<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome - Feinberg, J - 2017 | Cochrane Library</title> <meta content="Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome - Feinberg, J - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome - Feinberg, J - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012481.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome" name="citation_title"/> <meta content="Joshua Feinberg" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="wtv945@alumni.ku.dk" name="citation_author_email"/> <meta content="Emil Eik Nielsen" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Janette Greenhalgh" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Juliet Hounsome" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Naqash J Sethi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Sanam Safi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="The Capital Region, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012481.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/08/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Coronary Syndrome [mortality, *therapy]; Cause of Death; *Drug-Eluting Stents [adverse effects]; Randomized Controlled Trials as Topic; *Stents [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012481.pub2&amp;doi=10.1002/14651858.CD012481.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012481\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012481\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012481.pub2",title:"Drug\\u2010eluting stents versus bare\\u2010metal stents for acute coronary syndrome",firstPublishedDate:"Aug 23, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012481.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012481.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012481.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012481.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012481.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012481.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012481.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012481.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4427 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012481.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0173"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-sec-0157"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/appendices#CD012481-sec-0178"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/table_n/CD012481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/table_n/CD012481StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Joshua Feinberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0005">Emil Eik Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0006">Janette Greenhalgh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0007">Juliet Hounsome</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0008">Naqash J Sethi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0009">Sanam Safi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0010">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information#CD012481-cr-0011">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information/en#CD012481-sec-0193">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 August 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012481.pub2">https://doi.org/10.1002/14651858.CD012481.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012481-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012481-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012481-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012481-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012481-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012481-abs-0001" lang="en"> <section id="CD012481-sec-0001"> <h3 class="title" id="CD012481-sec-0001">Background</h3> <p>Approximately 3.7 million people died from acute coronary syndrome worldwide in 2012. Acute coronary syndrome, also known as myocardial infarction or unstable angina pectoris, is caused by a sudden blockage of the blood supplied to the heart muscle. Percutaneous coronary intervention is often used for acute coronary syndrome, but previous systematic reviews on the effects of drug‐eluting stents compared with bare‐metal stents have shown conflicting results with regard to myocardial infarction; have not fully taken account of the risk of random and systematic errors; and have not included all relevant randomised clinical trials. </p> </section> <section id="CD012481-sec-0002"> <h3 class="title" id="CD012481-sec-0002">Objectives</h3> <p>To assess the benefits and harms of drug‐eluting stents versus bare‐metal stents in people with acute coronary syndrome. </p> </section> <section id="CD012481-sec-0003"> <h3 class="title" id="CD012481-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, SCI‐EXPANDED, and BIOSIS from their inception to January 2017. We also searched two clinical trials registers, the European Medicines Agency and the US Food and Drug Administration databases, and pharmaceutical company websites. In addition, we searched the reference lists of review articles and relevant trials. </p> </section> <section id="CD012481-sec-0004"> <h3 class="title" id="CD012481-sec-0004">Selection criteria</h3> <p>Randomised clinical trials assessing the effects of drug‐eluting stents versus bare‐metal stents for acute coronary syndrome. We included trials irrespective of publication type, status, date, or language. </p> </section> <section id="CD012481-sec-0005"> <h3 class="title" id="CD012481-sec-0005">Data collection and analysis</h3> <p>We followed our published protocol and the methodological recommendations of Cochrane. Two review authors independently extracted data. We assessed the risks of systematic error by bias domains. We conducted Trial Sequential Analyses to control the risks of random errors. Our primary outcomes were all‐cause mortality, major cardiovascular events, serious adverse events, and quality of life. Our secondary outcomes were angina, cardiovascular mortality, and myocardial infarction. Our primary assessment time point was at maximum follow‐up. We assessed the quality of the evidence by the GRADE approach. </p> </section> <section id="CD012481-sec-0006"> <h3 class="title" id="CD012481-sec-0006">Main results</h3> <p>We included 25 trials randomising a total of 12,503 participants. All trials were at high risk of bias, and the quality of evidence according to GRADE was low to very low. We included 22 trials where the participants presented with ST‐elevation myocardial infarction, 1 trial where participants presented with non‐ST‐elevation myocardial infarction, and 2 trials where participants presented with a mix of acute coronary syndromes. </p> <p>Meta‐analyses at maximum follow‐up showed no evidence of a difference when comparing drug‐eluting stents with bare‐metal stents on the risk of all‐cause mortality or major cardiovascular events. The absolute risk of death was 6.97% in the drug‐eluting stents group compared with 7.74% in the bare‐metal stents group based on the risk ratio (RR) of 0.90 (95% confidence interval (CI) 0.78 to 1.03, 11,250 participants, 21 trials/22 comparisons, low‐quality evidence). The absolute risk of a major cardiovascular event was 6.36% in the drug‐eluting stents group compared with 6.63% in the bare‐metal stents group based on the RR of 0.96 (95% CI 0.83 to 1.11, 10,939 participants, 19 trials/20 comparisons, very low‐quality evidence). The results of Trial Sequential Analysis showed that we did not have sufficient information to confirm or reject our anticipated risk ratio reduction of 10% on either all‐cause mortality or major cardiovascular events at maximum follow‐up. </p> <p>Meta‐analyses at maximum follow‐up showed evidence of a benefit when comparing drug‐eluting stents with bare‐metal stents on the risk of a serious adverse event. The absolute risk of a serious adverse event was 18.04% in the drug‐eluting stents group compared with 23.01% in the bare‐metal stents group based on the RR of 0.80 (95% CI 0.74 to 0.86, 11,724 participants, 22 trials/23 comparisons, low‐quality evidence), and Trial Sequential Analysis confirmed this result. When assessing each specific type of adverse event included in the serious adverse event outcome separately, the majority of the events were target vessel revascularisation. When target vessel revascularisation was analysed separately, meta‐analysis showed evidence of a benefit of drug‐eluting stents, and Trial Sequential Analysis confirmed this result. </p> <p>Meta‐analyses at maximum follow‐up showed no evidence of a difference when comparing drug‐eluting stents with bare‐metal stents on the risk of cardiovascular mortality (RR 0.91, 95% CI 0.76 to 1.09, 9248 participants, 14 trials/15 comparisons, very low‐quality evidence) or myocardial infarction (RR 0.98, 95% CI 0.82 to 1.18, 10,217 participants, 18 trials/19 comparisons, very low‐quality evidence). The results of the Trial Sequential Analysis showed that we had insufficient information to confirm or reject our anticipated risk ratio reduction of 10% on cardiovascular mortality and myocardial infarction. </p> <p>No trials reported results on quality of life or angina.</p> </section> <section id="CD012481-sec-0007"> <h3 class="title" id="CD012481-sec-0007">Authors' conclusions</h3> <p>The current evidence suggests that drug‐eluting stents may lead to fewer serious adverse events compared with bare‐metal stents without increasing the risk of all‐cause mortality or major cardiovascular events. However, our Trial Sequential Analysis showed that there currently was not enough information to assess a risk ratio reduction of 10% for all‐cause mortality, major cardiovascular events, cardiovascular mortality, or myocardial infarction, and there were no data on quality of life or angina. The evidence in this review was of low to very low quality, and the true result may depart substantially from the results presented in this review. </p> <p>More randomised clinical trials with low risk of bias and low risks of random errors are needed if the benefits and harms of drug‐eluting stents for acute coronary syndrome are to be assessed properly. More data are needed on the outcomes all‐cause mortality, major cardiovascular events, quality of life, and angina to reduce the risk of random error. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012481-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012481-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012481-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012481-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012481-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012481-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012481-abs-0002" lang="en"> <h3>Benefits and harms of drug‐eluting versus bare‐metal stents in people with acute coronary syndrome </h3> <p><b>Background</b> </p> <p>Acute coronary syndrome is a term applied to heart attacks as well as chest pain during rest. The syndrome is caused by decreased blood supply to the heart due to either a narrowing of the vessels supplying the heart or a blood clot. According to the World Health Organization, 3.7 million people died from acute coronary syndrome in 2012. Percutaneous coronary intervention, commonly known as coronary angioplasty, is used to treat the narrowed or blocked vessel of the heart by inflating a balloon to allow blood to flow through the vessel again. Coronary stents are then inserted into the vessel to ensure it remains open. Two types of stents are available for use, a stent that is coated with a drug intended to reduce the risk of future blockages (drug‐eluting stent) and an uncoated stent (bare‐metal stent). In this review, we aimed to assess the benefits and harms of drug‐eluting stents compared with bare‐metal stents. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases from their inception to January 2017 and found 25 trials where people were randomly allocated to either a group receiving drug‐eluting stents or a group receiving bare‐metal stents. The 25 trials (26 comparisons) included 12,503 adults with a mean age of 60.8 years. </p> <p><b>Key results</b> </p> <p>The people receiving drug‐eluting stents did seem to have a reduced risk of experiencing a serious adverse event compared with those receiving bare‐metal stents, without affecting the risk of dying from any cause or specifically heart disease, or of having a heart attack. The serious adverse event likely to be avoided by those receiving drug‐eluting stents seems to be repeat balloon angioplasty. No data were reported on quality of life or chest pain (angina) after receiving the stent. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence should be interpreted with caution, as we judged the quality to be low to very low due to limitations of the included randomised clinical trials. The reason for the very low‐quality judgement was mainly due to all included trials being at high risk of bias. Consequently, the results may show more benefit of drug‐eluting stents than the 'real life' effect would show. Furthermore, most of the outcomes in our review lacked sufficient statistical power. Future well‐designed randomised clinical trials may therefore change the above‐mentioned results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012481-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012481-sec-0173"></div> <h3 class="title" id="CD012481-sec-0174">Implications for practice</h3> <section id="CD012481-sec-0174"> <p>The current evidence suggests that drug‐eluting stents may lead to fewer serious adverse events compared with bare‐metal stents. When assessing each specific type of event included in the serious adverse event outcome separately, we found that the majority of events were target vessel revascularisation. The reduction in serious adverse events came without increasing the risk of all‐cause mortality or major cardiovascular events. Our Trial Sequential Analysis showed that there was currently not enough information to assess a risk ratio reduction of 10% for all‐cause mortality, major cardiovascular events, cardiovascular mortality, or myocardial infarction, and there were no data on quality of life or angina. The evidence for the above outcomes was of low to very low quality, and the true result may depart substantially from the results presented in this systematic review. </p> </section> <h3 class="title" id="CD012481-sec-0175">Implications for research</h3> <section id="CD012481-sec-0175"> <p>Our Trial Sequential Analysis showed that there was currently not enough information to assess a risk ratio reduction of 10% for all‐cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction. We therefore recommend that future randomised clinical trials assessing these outcomes be conducted, as currently the superiority of drug‐eluting stents relies on a possible reduced risk of target vessel revascularisation. In addition, we found no trials reporting quality of life or angina, therefore future trials should also assess these outcomes. Furthermore, trials conducted up to now have not comprehensively reported serious adverse events, and future trials should avoid continuing this practice. Future trials should be conducted with low risk of systematic error and low risk of random errors. Such trials ought to be designed and reported according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and CONSORT guidelines (<a href="./references#CD012481-bbs2-0080" title="Chan A-W, TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža-JerićK , et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200-7.">Chan 2013</a>; <a href="./references#CD012481-bbs2-0166" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine2010;152(11):726-732.">Schulz 2010</a>). </p> <p>There is a need for systematic reviews assessing serious adverse events in quasi‐randomised and observational studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012481-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012481-sec-0008"></div> <div class="table" id="CD012481-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with acute coronary syndrome<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Drug‐eluting stents<br/><b>Comparison:</b> Bare‐metal stents </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bare‐metal stents</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with drug‐eluting stents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.78 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,250<br/>(21 RCTs/22 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (21 trials reporting on 22 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<br/>(60 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.74 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,724<br/>(22 RCTs/23 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that the boundary for benefit was breached, hence the risk of imprecision of the outcome result is low. Multiple eligible treatments were used in 1 trial, generating a further comparison (22 trials reporting on 23 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000<br/>(170 to 197) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major cardiovascular events at maximum<br/>follow‐up </p> <p>Follow‐up: median 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.83 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,939<br/>(19 RCTs/20 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (19 trials reporting on 20 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(55 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at maximum follow‐up ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.76 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9248<br/>(14 RCTs/15 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (14 trials reporting on 15 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(44 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.82 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,217<br/>(18 RCTs/19 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (18 trials reporting on 19 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(39 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angina at maximum follow‐up ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>RRR:</b> risk ratio reduction </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of imprecision due to our required information size not being met.<br/><sup>2</sup>Downgraded one level for serious risk of bias due to all trials being at high risk of bias, but as mortality is a more objective outcome, lack of blinding of participants, personnel and outcome assessors may not bias the outcome as much.<br/><sup>3</sup>Downgraded two levels for very serious risk of bias due to all trials being at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012481-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012481-sec-0009"></div> <section id="CD012481-sec-0010"> <h3 class="title" id="CD012481-sec-0010">Description of the condition</h3> <p>Cardiovascular disease, of which ischaemic heart disease is by far the largest component, is considered to be the number one cause of death globally (<a href="./references#CD012481-bbs2-0135" title="Lloyd-JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , De SimoneG , et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation2010;121(7):948-54. [PMID: 20177011]">Lloyd‐Jones 2010</a>; <a href="./references#CD012481-bbs2-0148" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2929. [PMID: 25139896]">Nichols 2014</a>; <a href="./references#CD012481-bbs2-0158" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25-146. [PMID: 18086926]">Rosamond 2008</a>). Ischaemic heart disease is generally divided into acute coronary syndrome and stable ischaemic heart disease (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). The disease remains prevalent, with more than 7 million people worldwide expected to develop acute coronary syndrome each year (<a href="./references#CD012481-bbs2-0195" title="WhiteHD , ChewDP . Acute myocardial infarction. Lancet2008;372(9638):570-84.">White 2008</a>). According to the World Health Organization, 7.4 million people died from ischaemic heart disease in 2012, representing 15% of all global deaths, with acute coronary syndrome accounting for approximately half of the deaths (<a href="./references#CD012481-bbs2-0190" title="TurpieAG . Burden of disease: medical and economic impact of acute coronary syndromes. American Journal of Managed Care2006;12(16 Suppl):S430-4.">Turpie 2006</a>; <a href="./references#CD012481-bbs2-0196" title="World Health Organization (WHO). Cardiovascular diseases. www.who.int/cardiovascular_diseases/en/ (accessed 27 January 2015).">WHO 2015</a>). The in‐hospital mortality proportions across different countries range from 5% to 10% (<a href="./references#CD012481-bbs2-0104" title="GuptaM , ChangWC , Van de WerfF , GrangerCB , MidodziW , BarbashG , et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction. European Heart Journal2003;24(18):1640-50.">Gupta 2003</a>). Ischaemic heart disease remains increasingly prevalent and costly to treat due to an increase in life expectancy and a decrease in death rates (<a href="./references#CD012481-bbs2-0082" title="CooperR , CutlerJ , Desvigne-NickensP , FortmannSP , FriedmanL , HavlikR , et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation2000;102(25):3137-47. [PMID: 11120707]">Cooper 2000</a>; <a href="./references#CD012481-bbs2-0164" title="SchmidtM , JacobsenJB , LashTL , BøtkerHE , SørensenHT . 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ2012;344:e356. [PMID: 22279115]">Schmidt 2012</a>). </p> <p>Acute coronary syndrome is a collective term for the following:</p> <p> <ol id="CD012481-list-0001"> <li> <p>unstable angina pectoris (myocardial ischaemia at rest or minimal exertion in the absence of cardiomyocyte necrosis) (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>); </p> </li> <li> <p>non‐ST‐segment elevation myocardial infarction (NSTEMI); and</p> </li> <li> <p>ST‐segment elevation myocardial infarction (STEMI) (<a href="./references#CD012481-bbs2-0070" title="AmsterdamEA , WengerNK , BrindisRG , Casey DE Jr, GaniatsTG , Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;130(25):2354-94.">Amsterdam 2014</a>). Myocardial infarction can be recognised by clinical features, electrocardiographic (ECG) findings, elevated values of biochemical markers (biomarkers) of myocardial necrosis, imaging, or pathology (<a href="./references#CD012481-bbs2-0188" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD , Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Global Heart2012;7(4):275-95. [PMID: 25689940]">Thygesen 2012</a>). The diagnosis of myocardial infarction is dependent on an elevation of the serum levels of cardiac‐specific troponin I, troponin T, or the myocardial band isoenzyme of creatine kinase (CK‐MB), among others (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). Cardiac troponin levels will usually be positive within one hour in people with myocardial infarction when using high‐sensitivity assays (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). If the initial test is negative, a repeat test is advisable after three hours to rule out a myocardial infarction, since in some cases there is a delay in the elevation of cardiac enzymes (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). The changes in the ST‐segment reflected in an ECG provide the basis for the distinction between NSTEMI and STEMI (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). Compared to NSTEMI and STEMI, unstable angina pectoris presents without the characteristic rise in cardiac‐specific biomarkers (<a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). </p> </li> </ol> </p> <p>For research purposes, the causes of myocardial infarction are generally divided into five main classes (<a href="./references#CD012481-bbs2-0188" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD , Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Global Heart2012;7(4):275-95. [PMID: 25689940]">Thygesen 2012</a>). </p> <p> <ul id="CD012481-list-0002"> <li> <p>Type 1: spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries often caused by coronary artery disease. </p> </li> <li> <p>Type 2: myocardial infarction secondary to an ischaemic imbalance, such as coronary artery spasm, coronary embolism, anaemia, arrhythmias, hypertension, or hypotension. </p> </li> <li> <p>Type 3: myocardial infarction with symptoms suggestive of myocardial ischaemia and resulting in sudden unexpected cardiac death when biomarker values are unavailable or unobtainable before death. </p> </li> <li> <p>Type 4a: myocardial infarction associated with percutaneous coronary intervention.</p> </li> <li> <p>Type 4b: myocardial infarction associated with stent thrombosis, as documented by angiography or at autopsy. </p> </li> <li> <p>Type 5: myocardial infarction associated with coronary artery bypass graft.</p> </li> </ul> </p> <section id="CD012481-sec-0011"> <h4 class="title">Major complications associated with myocardial infarction</h4> <p> <ul id="CD012481-list-0003"> <li> <p>Life‐threatening ventricular arrhythmias caused by changes in the electrophysiologic characteristics of the myocyte, electrolyte imbalance, continuous ischaemia, and variations in heart rate, which are all due to obstruction and hence reduced flow to the myocardium and myocardial necrosis (<a href="./references#CD012481-bbs2-0074" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012481-bbs2-0177" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Mechanical complications caused by necrosis of the myocardium, such as ventricular wall rupture, septum rupture, and papillary muscle rupture (<a href="./references#CD012481-bbs2-0074" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012481-bbs2-0152" title="Pohjola-SintonenS , MullerJE , StonePH , WillichSN , AntmanEM , DavisVG , et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. American Heart Journal1989;117(4):809-18.">Pohjola‐Sintonen 1989</a>; <a href="./references#CD012481-bbs2-0177" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Cardiogenic shock caused by failure of the ventricle to pump an adequate amount of blood leading to systemic hypotension (<a href="./references#CD012481-bbs2-0074" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012481-bbs2-0177" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Acute decompensated heart failure caused by impairment in systolic and diastolic function due to myocardial ischaemia (<a href="./references#CD012481-bbs2-0074" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart2009;95(11):888-94.">Brieger 2009</a>). </p> </li> <li> <p>Depression (<a href="./references#CD012481-bbs2-0185" title="ThombsBD , BassEB , FordDE , StewartKJ , TsilidisKK , PatelU , et al. Prevalence of depression in survivors of acute myocardial infarction. Journal of General Internal Medicine2006;21(1):30-8.">Thombs 2006</a>). </p> </li> </ul> </p> <p>A narrowing of a coronary vessel causes unstable angina due to one of five reasons:</p> <p> <ol id="CD012481-list-0004"> <li> <p>non‐occlusive thrombus on pre‐existing plaques;</p> </li> <li> <p>dynamic obstruction, i.e. coronary vasoconstriction;</p> </li> <li> <p>progressive mechanical obstruction, such as restenosis after percutaneous coronary intervention; </p> </li> <li> <p>inflammation or infection; and</p> </li> <li> <p>secondary unstable angina due to conditions increasing the oxygen demand, such as hypertension, thyrotoxicosis, and tachycardia (<a href="./references#CD012481-bbs2-0072" title="BraunwaldE . Unstable angina: an etiologic approach to management. Circulation1998;98(21):2219-22.">Braunwald 1998</a>; <a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). Unstable angina is associated with lower mortality compared to myocardial infarction but similar rates of rehospitalisations; however, the patient may have a worse quality of life (<a href="./references#CD012481-bbs2-0092" title="DudasK , BjörckL , JernbergT , LappasG , WallentinL , RosengrenA . Differences between acute myocardial infarction and unstable angina: a longitudinal cohort study reporting findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA). BMJ Open2013;3(1):e002155.">Dudas 2013</a>; <a href="./references#CD012481-bbs2-0139" title="MaddoxTM , ReidKJ , RumsfeldJS , SpertusJA . One-year health status outcomes of unstable angina versus myocardial infarction: a prospective, observational cohort study of ACS survivors. BMC Cardiovascular Disorders2007;7:28.">Maddox 2007</a>; <a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). People with unstable angina are also at risk of cardiogenic shock (<a href="./references#CD012481-bbs2-0161" title="Ruiz-BailénM , Rucabado-AguilarL , Castillo-RiveraAM , Expósito-RuizM , Morante-ValleA , Rodríguez-GarcíaJJ , et al. Cardiogenic shock in acute coronary syndrome in the Spanish population. Medical Science Monitor2008;14(11):PH46-57.">Ruiz‐Bailén 2008</a>). </p> </li> </ol> </p> <p>Historically, the degree of luminal stenosis and the number of coronary arteries involved (single‐, double‐, or triple‐vessel disease) have defined the severity of ischaemic heart disease (<a href="./references#CD012481-bbs2-0156" title="RingqvistI , FisherLD , MockM , DavisKB , WedelH , ChaitmanBR , et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). Journal of Clinical Investigation1983;71(6):1854-66. [PMID: 6863543]">Ringqvist 1983</a>). Researchers have since developed more comprehensive scoring systems (<a href="./references#CD012481-bbs2-0099" title="GensiniGG . A more meaningful scoring system for determining the severity of coronary heart disease. American Journal of Cardiology1983;51(3):606. [PMID: 6823874]">Gensini 1983</a>; <a href="./references#CD012481-bbs2-0167" title="SeizerA . On the limitation of therapeutic intervention trials in ischemic heart disease: a clinican's viewpoint. American Journal of Cardiology1982;49(1):252-5.">Seizer 1982</a>). Coronary angiography score and two additional scores, that is vascular scoring and stenosis scoring, determine the Gensini score (<a href="./references#CD012481-bbs2-0099" title="GensiniGG . A more meaningful scoring system for determining the severity of coronary heart disease. American Journal of Cardiology1983;51(3):606. [PMID: 6823874]">Gensini 1983</a>). The results of the coronary angiography determine the SYNTAX score, which takes into account lesion complexity, lesion location, and number of lesions (<a href="./references#CD012481-bbs2-0171" title="SianosG , MorelMA , KappeteinAP , MoriceMC , ColomboA , DawkinsK , et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention2005;1(2):219-27. [PMID: 19758907]">Sianos 2005</a>). The SYNTAX score II is used to improve the decision‐making in choosing between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for a long‐term, individualised risk assessment in people with complex ischaemic heart disease. The SYNTAX score II combines the anatomical‐based SYNTAX score (<a href="./references#CD012481-bbs2-0171" title="SianosG , MorelMA , KappeteinAP , MoriceMC , ColomboA , DawkinsK , et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention2005;1(2):219-27. [PMID: 19758907]">Sianos 2005</a>), as well as seven clinical variables (creatinine clearance, peripheral vascular disease, unprotected left main coronary disease, sex, chronic obstructive pulmonary disease, age, and left ventricular ejection fraction) (<a href="./references#CD012481-bbs2-0096" title="FarooqV , vanKlaverenD , SteyerbergEW , MeligaE , VergouweY , ChieffoA , et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet2013;381(9867):639-50.">Farooq 2013</a>; <a href="./references#CD012481-bbs2-0171" title="SianosG , MorelMA , KappeteinAP , MoriceMC , ColomboA , DawkinsK , et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention2005;1(2):219-27. [PMID: 19758907]">Sianos 2005</a>). </p> <p>A glossary of medical terms is in <a href="./appendices#CD012481-sec-0179">Appendix 1</a>. </p> </section> </section> <section id="CD012481-sec-0012"> <h3 class="title" id="CD012481-sec-0012">Description of the intervention</h3> <p>Percutaneous coronary intervention is performed by inserting an access sheath into a peripheral artery (most often the femoral artery or the radial artery); a catheter is advanced, under X‐ray screening, through the blood vessels to the aortic root, at the origin of the coronary arteries. Other tools such as balloons and stents can then be advanced down the artery, over a guide wire, to the location of the narrowing or blockage (<a href="./references#CD012481-bbs2-0078" title="CantorWJ , PuleyG , NatarajanMK , DzavikV , MadanM , FryA , et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction - the RADIAL-AMI pilot randomized trial. American Heart Journal2005;150(3):543-9. [PMID: 16169338]">Cantor 2005</a>; <a href="./references#CD012481-bbs2-0106" title="HamonM , RasmussenLH , ManoukianSV , CequierA , LincoffMA , RupprechtHJ , et al. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention2009;5(1):115-20. [PMID: 19577992]">Hamon 2009</a>). Andreas Roland Grüntzig performed the first percutaneous coronary intervention in 1977 (<a href="./references#CD012481-bbs2-0102" title="GrüntzigA . Transluminal dilatation of coronary-artery stenosis. Lancet1978;1(8058):263. [PMID: 74678]">Grüntzig 1978</a>). Percutaneous coronary intervention has since then evolved to become one of the cornerstones in the treatment of ischaemic heart disease. </p> <p>Percutaneous coronary intervention in people with acute coronary syndrome can be performed both as primary percutaneous coronary intervention (primary PCI) and secondary percutaneous coronary intervention (secondary PCI) (<a href="./references#CD012481-bbs2-0140" title="MeyerJ , SchmitzH , ErbelR , KiesslichT , Böcker-JosephsB , KrebsW , et al. Treatment of unstable angina pectoris with percutaneous transluminal coronary angioplasty (PTCA). Catheterization and Cardiovascular Diagnosis1981;7(4):361-71.">Meyer 1981</a>; <a href="./references#CD012481-bbs2-0141" title="MeyerJ , MerxW , DörrR , LambertzH , BethgeC , EffertS . Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). American Heart Journal1982;103(1):132-4.">Meyer 1982</a>; <a href="./references#CD012481-bbs2-0142" title="MeyerJ , MerxW , SchmitzH , ErbelR , KiesslichT , DörrR , et al. Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation1982;66(5):905-13.">Meyer 1982a</a>; <a href="./references#CD012481-bbs2-0143" title="MeyerJ , SchmitzHJ , KiesslichT , ErbelR , KrebsW , SchulzW , et al. Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. American Heart Journal1983;106(5 Pt 1):973-80.">Meyer 1983</a>). Primary PCI may be performed in the acute phase of myocardial infarction if patients present with STEMI. Patients presenting with NSTEMI or unstable angina pectoris that is characterised as high‐risk acute coronary syndrome may also benefit from undergoing angiography and percutaneous coronary intervention either immediately or as part of an early (within 24 hours) invasive strategy (<a href="./references#CD012481-bbs2-0115" title="HoenigMR , AroneyCN , ScottIA . Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004815. [DOI: 10.1002/14651858.CD004815.pub4]">Hoenig 2010</a>; <a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). The high‐risk factors include haemodynamic instability, severe left ventricular dysfunction, recurrent or persistent rest angina, mechanical complications, sustained ventricular tachycardia, and dynamic ST‐T wave electrocardiographic changes (<a href="./references#CD012481-bbs2-0115" title="HoenigMR , AroneyCN , ScottIA . Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD004815. [DOI: 10.1002/14651858.CD004815.pub4]">Hoenig 2010</a>). </p> <p>Secondary PCI includes both subacute PCI and elective PCI. Subacute PCI is generally performed within the first 72 hours after symptom debut in people with unstable angina pectoris or NSTEMI who are not candidates for primary PCI because of being haemodynamically stable with medical therapy and not at high risk (<a href="./references#CD012481-bbs2-0073" title="BreallJA , AroestyJM , SimonsM . Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction. www.uptodate.com/contents/overview-of-the-non-acute-management-of-unstable-angina-and-non-st-elevation-myocardial-infarction (accessed 19 November 2015).">Breall 2016</a>; <a href="./references#CD012481-bbs2-0157" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). Elective PCI is performed in patients where coronary artery bypass grafting is not indicated, as well as in patients who are dissatisfied with their quality of life because of symptoms related to ischaemic heart disease or with adverse events due to their medical treatment (<a href="./references#CD012481-bbs2-0132" title="LevinT , AroestyJM . Stable ischemic heart disease: indications for revascularization. www.uptodate.com/contents/stable-ischemic-heart-disease-indications-for-revascularization (accessed 10 September 2015).">Levin 2016</a>). </p> <p>The first percutaneous coronary intervention was performed by inflating a balloon at the blockage of the coronary artery to dilate the artery ('balloon angioplasty') (<a href="./references#CD012481-bbs2-0102" title="GrüntzigA . Transluminal dilatation of coronary-artery stenosis. Lancet1978;1(8058):263. [PMID: 74678]">Grüntzig 1978</a>; <a href="./references#CD012481-bbs2-0103" title="GrüntzigAR , SenningA , SiegenthalerWE . Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. New England Journal of Medicine1979;301(2):61-8. [PMID: 449946]">Grüntzig 1979</a>). The healing properties of the treatment seem to be related to the percutaneous coronary intervention expanding the outer diameter of the blocked coronary artery and not by decompression of the arterial plaque (<a href="./references#CD012481-bbs2-0091" title="DüberC , JungbluthA , RumpeltHJ , ErbelR , MeyerJ , ThoenesW . Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. American Journal of Cardiology1986;58(9):698-703.">Düber 1986</a>). Balloon angioplasty, however, generally did not seem to achieve a long‐lasting result, with restenosis occurring over time (<a href="./references#CD012481-bbs2-0086" title="DangasG , KuepperF . Restenosis: repeat narrowing of a coronary artery. Circulation2002;105(22):2586.">Dangas 2002</a>; <a href="./references#CD012481-bbs2-0153" title="PuelJ , JuilliereY , BertrandME , RickardsAF , SigwartU , SerruysPW . Early and late assessment of stenosis geometry after coronary arterial stenting. American Journal of Cardiology1988;61(8):546-53.">Puel 1988</a>). In an attempt to keep the lumen open longer, the next development was a small metallic scaffold called a 'stent'. These tubular devices are expanded over a balloon and press against the walls of the artery to keep it open (<a href="./references#CD012481-bbs2-0153" title="PuelJ , JuilliereY , BertrandME , RickardsAF , SigwartU , SerruysPW . Early and late assessment of stenosis geometry after coronary arterial stenting. American Journal of Cardiology1988;61(8):546-53.">Puel 1988</a>). These first devices were subsequently termed 'bare‐metal stents' (after the later introduction of 'drug‐eluting stents') and had improved outcomes over balloon angioplasty, but were still associated with high rates of restenosis over time (<a href="./references#CD012481-bbs2-0084" title="CutlipDE , ChauhanMS , BaimDS , HoKK , PopmaJJ , CarrozzaJP , et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. Journal of the American College of Cardiology2002;40(12):2082-9.">Cutlip 2002</a>; <a href="./references#CD012481-bbs2-0094" title="ErbelR , HaudeM , HöppHW , FranzenD , RupprechtHJ , HeubleinB , et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. New England Journal of Medicine1998;339(23):1672-8.">Erbel 1998</a>; <a href="./references#CD012481-bbs2-0097" title="FischmanDL , LeonMB , BaimDS , SchatzRA , SavageMP , PennI , et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. New England Journal of Medicine1994;331(8):496-501. [PMID: 8041414]">Fischman 1994</a>; <a href="./references#CD012481-bbs2-0138" title="MacayaC , SerruysPW , RuygrokP , SuryapranataH , MastG , KlugmannS , et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. Journal of the American College of Cardiology1996;27(2):255-61. [PMID: 8557891]">Macaya 1996</a>; <a href="./references#CD012481-bbs2-0153" title="PuelJ , JuilliereY , BertrandME , RickardsAF , SigwartU , SerruysPW . Early and late assessment of stenosis geometry after coronary arterial stenting. American Journal of Cardiology1988;61(8):546-53.">Puel 1988</a>; <a href="./references#CD012481-bbs2-0168" title="SerruysPW , deJaegereP , KiemeneijF , MacayaC , RutschW , HeyndrickxG , et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. New England Journal of Medicine1994;331(8):489-95. [PMID: 8041413]">Serruys 1994</a>; <a href="./references#CD012481-bbs2-0169" title="SerruysPW , vanHoutB , BonnierH , LegrandV , GarciaE , MacayaC , et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet1998;352(9129):673-81. [PMID: 9728982]">Serruys 1998</a>). A Cochrane review from 2005 found that primary stenting versus balloon angioplasty alone seemed to reduce the rate of reinfarction and target vessel revascularisation (<a href="./references#CD012481-bbs2-0149" title="NordmannAJ , BucherHC , HengstlerP , HarrT , YoungJ . Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD005313. [DOI: 10.1002/14651858.CD005313]">Nordmann 2005</a>). </p> <p>The next stents were drug‐eluting stents consisting of three main components:</p> <p> <ol id="CD012481-list-0005"> <li> <p>a metal mesh;</p> </li> <li> <p>an antiproliferative drug (e.g. sirolimus, paclitaxel, zotarolimus, or everolimus); and </p> </li> <li> <p>a polymer used to coat the metal mesh.</p> </li> </ol> </p> <p>Antiproliferative drugs to limit the excessive growth of neointima using cytotoxic or cytostatic agents, as well as a polymer to control the release of the antiproliferative drug, supplemented the metal mesh (<a href="./references#CD012481-bbs2-0087" title="DegertekinM , RegarE , TanabeK , LeeCH , SerruysPW . Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiologica2002;50(5):405-18. [PMID: 12384623]">Degertekin 2002</a>; <a href="./references#CD012481-bbs2-0095" title="FajadetJ , WijnsW , LaarmanGJ , KuckKH , OrmistonJ , MünzelT , et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation2006;114(8):798-806. [PMID: 16908773]">Fajadet 2006</a>; <a href="./references#CD012481-bbs2-0116" title="Holmes DR Jr, LeonMB , MosesJW , PopmaJJ , CutlipD , FitzgeraldPJ , et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation2004;109(5):634-40. [PMID: 14769686]">Holmes 2004</a>; <a href="./references#CD012481-bbs2-0130" title="LeeMS , ShahAP , AragonJ , JamaliA , DohadS , KarS , et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheterization &amp; Cardiovascular Interventions2005;66(4):507-11. [PMID: 16270361]">Lee 2005</a>; <a href="./references#CD012481-bbs2-0145" title="MoriceMC , SerruysPW , SousaJE , FajadetJ , Ban HayashiE , PerinM , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine2002;346(23):1773-80. [PMID: 12050336]">Morice 2002</a>; <a href="./references#CD012481-bbs2-0146" title="MosesJW , LeonMB , PopmaJJ , FitzgeraldPJ , HolmesDR , O'ShaughnessyC , et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine2003;349(14):1315-23. [PMID: 14523139]">Moses 2003</a>; <a href="./references#CD012481-bbs2-0178" title="StoneGW , EllisSG , CoxDA , HermillerJ , O'ShaughnessyC , MannJT , et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine2004;350(3):221-31. [PMID: 14724301]">Stone 2004</a>; <a href="./references#CD012481-bbs2-0179" title="StoneGW , EllisSG , CoxDA , HermillerJ , O'ShaughnessyC , MannJT , et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation2004;109(16):1942-7. [PMID: 15078803]">Stone 2004a</a>). </p> <p>Newer drug‐eluting stents have decreased strut thickness and are meant to have improved flexibility/deliverability, enhanced polymer biocompatibility/drug‐eluting profiles, and superior re‐endothelialisation kinetics (<a href="./references#CD012481-bbs2-0170" title="SerruysPW , SilberS , GargS , vanGeunsRJ , RichardtG , BuszmanPE , et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. New England Journal of Medicine2010;363(2):136-46. [PMID: 20554978]">Serruys 2010</a>; <a href="./references#CD012481-bbs2-0180" title="StoneGW , RizviA , NewmanW , MastaliK , WangJC , CaputoR , et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine2010;362(18):1663-74.">Stone 2010</a>). They typically use everolimus or zotarolimus as their antiproliferative drug (<a href="./references#CD012481-bbs2-0170" title="SerruysPW , SilberS , GargS , vanGeunsRJ , RichardtG , BuszmanPE , et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. New England Journal of Medicine2010;363(2):136-46. [PMID: 20554978]">Serruys 2010</a>; <a href="./references#CD012481-bbs2-0180" title="StoneGW , RizviA , NewmanW , MastaliK , WangJC , CaputoR , et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine2010;362(18):1663-74.">Stone 2010</a>). </p> <p>The polymer‐coating of the drug‐eluting stents has, however, been linked with adverse events, such as stent thrombosis (<a href="./references#CD012481-bbs2-0081" title="ChenW , HabrakenTC , HenninkWE , KokRJ . Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjugate Chemistry2015;26(7):1277-88. [PMID: 26041505]">Chen 2015</a>). Both drug‐eluting stents with a biodegradable polymer as well as polymer‐free drug‐eluting stents have therefore been developed. Polymer‐free drug‐eluting stents use the same antiproliferative drugs (such as paclitaxel or sirolimus) as the polymer drug‐eluting stents (<a href="./references#CD012481-bbs2-0068" title="AbizaidA , Costa JR Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circulation: Cardiovascular Interventions2010;3(4):384-93.">Abizaid 2010</a>; <a href="./references#CD012481-bbs2-0081" title="ChenW , HabrakenTC , HenninkWE , KokRJ . Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjugate Chemistry2015;26(7):1277-88. [PMID: 26041505]">Chen 2015</a>). </p> <p>In an attempt to further reduce the risk of restenosis, bioresorbable (also called biodegradable) stents were developed. The principal components of the bioresorbable stent are the same as the drug‐eluting stents; in most cases, a polylactic acid mesh replaces the metal mesh (<a href="./references#CD012481-bbs2-0108" title="HaudeM , ErbelR , ErneP , VerheyeS , DegenH , BöseD , et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet2013;381(9869):836-44.">Haude 2013</a>; <a href="./references#CD012481-bbs2-0154" title="PuricelS , ArroyoD , CorpatauxN , BaeriswylG , LehmannS , KallinikouZ , et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Journal of the American College of Cardiology2015;65(8):791-801.">Puricel 2015</a>). The polylactic acid mesh is broken down and removed over time (<a href="./references#CD012481-bbs2-0183" title="TamaiH , IgakiK , KyoE , KosugaK , KawashimaA , MatsuiS , et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation2000;102(4):399-404.">Tamai 2000</a>). The same types of drugs (everolimus, paclitaxel, sirolimus) used in drug‐eluting stents along with Biolimus are used in bioresorbable stents (<a href="./references#CD012481-bbs2-0108" title="HaudeM , ErbelR , ErneP , VerheyeS , DegenH , BöseD , et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet2013;381(9869):836-44.">Haude 2013</a>; <a href="./references#CD012481-bbs2-0109" title="HaudeM , InceH , AbizaidA , ToelgR , LemosPA , vonBirgelenC , et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet2016;387(10013):31-9.">Haude 2016</a>; <a href="./references#CD012481-bbs2-0154" title="PuricelS , ArroyoD , CorpatauxN , BaeriswylG , LehmannS , KallinikouZ , et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Journal of the American College of Cardiology2015;65(8):791-801.">Puricel 2015</a>). </p> <p>Bare‐metal stents, drug‐eluting stents, and bioresorbable stents are used in modern percutaneous coronary interventions, with drug‐eluting stents generally being the first choice (<a href="./references#CD012481-bbs2-0197" title="WindeckerS , KolhP , AlfonsoF , ColletJP , CremerJ , FalkV , et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal2014;35(37):2541-619.">Windecker 2014</a>). Guidelines recommend that acute coronary syndrome patients receive 12 months of antiplatelet therapy (aspirin plus a G protein‐coupled purinergic (P2Y12 receptor) blocker) regardless of whether percutaneous coronary intervention is performed (<a href="./references#CD012481-bbs2-0197" title="WindeckerS , KolhP , AlfonsoF , ColletJP , CremerJ , FalkV , et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal2014;35(37):2541-619.">Windecker 2014</a>). The recommended minimum length of duration of antiplatelet therapy for the implant of the bare‐metal stents and drug‐eluting stents is one month and six months, respectively (<a href="./references#CD012481-bbs2-0197" title="WindeckerS , KolhP , AlfonsoF , ColletJP , CremerJ , FalkV , et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal2014;35(37):2541-619.">Windecker 2014</a>). </p> <p>Adverse events associated with percutaneous coronary intervention include death, coronary artery complications (such as perforation of the artery, distal embolisation (passage of an intravascular mass, which is capable of clogging capillaries), or stent thrombosis), myocardial infarction (type 4 myocardial infarction) (<a href="./references#CD012481-bbs2-0188" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD , Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Global Heart2012;7(4):275-95. [PMID: 25689940]">Thygesen 2012</a>), vascular complications (such as bleeding or infection at the access site, retroperitoneal bleeding, or atheroembolism), stroke, and acute kidney failure (<a href="./references#CD012481-bbs2-0071" title="BaimDS , GrossmanW . Complications of cardiac catheterization. In: BaimDS , GrossmanW , editors(s). Cardiac Catheterization, Angiography and Intervention. Williams &amp; Wilkins, 1996:17.">Baim 1996</a>; <a href="./references#CD012481-bbs2-0077" title="CantorWJ , LazzamC , CohenEA , BowmanKA , DolmanS , MackieK , et al. Failed coronary stent deployment. American Heart Journal1998;136(6):1088-95.">Cantor 1998</a>; <a href="./references#CD012481-bbs2-0173" title="StankovicG , OrlicD , CorvajaN , AiroldiF , ChieffoA , SpanosV , et al. Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. American Journal of Cardiology2004;93(2):213-6.">Stankovic 2004</a>). </p> </section> <section id="CD012481-sec-0013"> <h3 class="title" id="CD012481-sec-0013">How the intervention might work</h3> <p>Percutaneous coronary intervention aims to decrease the stenosis of the coronary artery resulting in increased blood flow to the myocardium of the heart, which is thought to limit ischaemia and potentially reinfarction. Drug‐eluting stents may be more beneficial than bare‐metal stents because they release antiproliferative drugs, which may limit neointimal growth (<a href="./references#CD012481-bbs2-0087" title="DegertekinM , RegarE , TanabeK , LeeCH , SerruysPW . Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiologica2002;50(5):405-18. [PMID: 12384623]">Degertekin 2002</a>; <a href="./references#CD012481-bbs2-0095" title="FajadetJ , WijnsW , LaarmanGJ , KuckKH , OrmistonJ , MünzelT , et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation2006;114(8):798-806. [PMID: 16908773]">Fajadet 2006</a>; <a href="./references#CD012481-bbs2-0116" title="Holmes DR Jr, LeonMB , MosesJW , PopmaJJ , CutlipD , FitzgeraldPJ , et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation2004;109(5):634-40. [PMID: 14769686]">Holmes 2004</a>; <a href="./references#CD012481-bbs2-0130" title="LeeMS , ShahAP , AragonJ , JamaliA , DohadS , KarS , et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheterization &amp; Cardiovascular Interventions2005;66(4):507-11. [PMID: 16270361]">Lee 2005</a>; <a href="./references#CD012481-bbs2-0145" title="MoriceMC , SerruysPW , SousaJE , FajadetJ , Ban HayashiE , PerinM , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. New England Journal of Medicine2002;346(23):1773-80. [PMID: 12050336]">Morice 2002</a>; <a href="./references#CD012481-bbs2-0146" title="MosesJW , LeonMB , PopmaJJ , FitzgeraldPJ , HolmesDR , O'ShaughnessyC , et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine2003;349(14):1315-23. [PMID: 14523139]">Moses 2003</a>; <a href="./references#CD012481-bbs2-0178" title="StoneGW , EllisSG , CoxDA , HermillerJ , O'ShaughnessyC , MannJT , et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine2004;350(3):221-31. [PMID: 14724301]">Stone 2004</a>; <a href="./references#CD012481-bbs2-0179" title="StoneGW , EllisSG , CoxDA , HermillerJ , O'ShaughnessyC , MannJT , et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation2004;109(16):1942-7. [PMID: 15078803]">Stone 2004a</a>). The new bioresorbable stents as well as the polymer‐free drug‐eluting stents may be even more beneficial since they remove material that has been associated with adverse events (<a href="./references#CD012481-bbs2-0068" title="AbizaidA , Costa JR Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circulation: Cardiovascular Interventions2010;3(4):384-93.">Abizaid 2010</a>; <a href="./references#CD012481-bbs2-0081" title="ChenW , HabrakenTC , HenninkWE , KokRJ . Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjugate Chemistry2015;26(7):1277-88. [PMID: 26041505]">Chen 2015</a>; <a href="./references#CD012481-bbs2-0108" title="HaudeM , ErbelR , ErneP , VerheyeS , DegenH , BöseD , et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet2013;381(9869):836-44.">Haude 2013</a>; <a href="./references#CD012481-bbs2-0154" title="PuricelS , ArroyoD , CorpatauxN , BaeriswylG , LehmannS , KallinikouZ , et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Journal of the American College of Cardiology2015;65(8):791-801.">Puricel 2015</a>). </p> </section> <section id="CD012481-sec-0014"> <h3 class="title" id="CD012481-sec-0014">Why it is important to do this review</h3> <p>The prevalence of ischaemic heart disease is considerable and causes one‐third of all deaths in people over 35 years of age (<a href="./references#CD012481-bbs2-0135" title="Lloyd-JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , De SimoneG , et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation2010;121(7):948-54. [PMID: 20177011]">Lloyd‐Jones 2010</a>; <a href="./references#CD012481-bbs2-0148" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2929. [PMID: 25139896]">Nichols 2014</a>; <a href="./references#CD012481-bbs2-0158" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25-146. [PMID: 18086926]">Rosamond 2008</a>). Beneficial treatments can therefore alleviate a considerable disease burden and healthcare cost. Former reviews have found conflicting evidence of the efficacy and safety of drug‐eluting stents versus bare‐metal stents. </p> <p>A 2010 Cochrane review compared drug‐eluting stents versus bare‐metal stents in participants with both acute coronary syndrome and stable ischaemic heart disease (<a href="./references#CD012481-bbs2-0101" title="GreenhalghJ , HockenhullJ , RaoN , DundarY , DicksonRC , BagustA . Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD004587. [DOI: 10.1002/14651858.CD004587.pub3]">Greenhalgh 2010</a>). The authors found no significant difference on all‐cause mortality, incidence of acute myocardial infarction, or thrombosis. However, the review showed indications of beneficial effects of drug‐eluting stents compared with bare‐metal stents on target lesion revascularisation, target vessel revascularisation, and a composite outcome of cardiac events. </p> <p>Six non‐Cochrane reviews compared drug‐eluting stents with bare‐metal stents in participants with ischaemic heart disease (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0126" title="KastratiA , MehilliJ , PacheJ , KaiserC , ValgimigliM , KelbaekH , et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine2007;356(10):1030-9. [PMID: 17296823]">Kastrati 2007</a>; <a href="./references#CD012481-bbs2-0159" title="RoukozH , BavryAA , SarkeesML , MoodGR , KumbhaniDJ , RabbatMG , et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine2009;122(6):581. [PMID: 19486720]">Roukoz 2009</a>; <a href="./references#CD012481-bbs2-0176" title="StettlerC , WandelS , AllemannS , KastratiA , MoriceMC , SchömigA , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet2007;370(9591):937-48. [PMID: 17869634]">Stettler 2007</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>; <a href="./references#CD012481-bbs2-0200" title="ZhengF , XingS , GongZ , XingQ . Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart, Lung &amp; Circulation2014;23(6):542-8. [PMID: 24529648]">Zheng 2014</a>). Three reviews included only STEMI patients (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>; <a href="./references#CD012481-bbs2-0200" title="ZhengF , XingS , GongZ , XingQ . Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart, Lung &amp; Circulation2014;23(6):542-8. [PMID: 24529648]">Zheng 2014</a>). Two of these reviews found no difference between drug‐eluting stents versus bare‐metal stents on all‐cause mortality and stent thrombosis, but a beneficial effect on target vessel revascularisation (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a> observed improvement of recurrent myocardial infarction with drug‐eluting stents, while <a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a> found no effect. <a href="./references#CD012481-bbs2-0200" title="ZhengF , XingS , GongZ , XingQ . Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart, Lung &amp; Circulation2014;23(6):542-8. [PMID: 24529648]">Zheng 2014</a>, which included only four trials, compared the effects of bare‐metal stents with drug‐eluting stents in STEMI participants at five‐year follow‐up. The review found that there was no difference in the interventions with regard to all‐cause mortality and acute myocardial infarction, as well as no effect on thrombosis, except for its occurrence later than one year after percutaneous coronary intervention. Three reviews assessed the effects of drug‐eluting stents versus bare‐metal stents in participants with ischaemic heart disease (including STEMI, NSTEMI, unstable angina pectoris, and stable angina pectoris) (<a href="./references#CD012481-bbs2-0126" title="KastratiA , MehilliJ , PacheJ , KaiserC , ValgimigliM , KelbaekH , et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine2007;356(10):1030-9. [PMID: 17296823]">Kastrati 2007</a>; <a href="./references#CD012481-bbs2-0159" title="RoukozH , BavryAA , SarkeesML , MoodGR , KumbhaniDJ , RabbatMG , et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine2009;122(6):581. [PMID: 19486720]">Roukoz 2009</a>; <a href="./references#CD012481-bbs2-0176" title="StettlerC , WandelS , AllemannS , KastratiA , MoriceMC , SchömigA , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet2007;370(9591):937-48. [PMID: 17869634]">Stettler 2007</a>). Of the three reviews, two compared sirolimus stents and paclitaxel stents with bare‐metal stents (<a href="./references#CD012481-bbs2-0159" title="RoukozH , BavryAA , SarkeesML , MoodGR , KumbhaniDJ , RabbatMG , et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine2009;122(6):581. [PMID: 19486720]">Roukoz 2009</a>; <a href="./references#CD012481-bbs2-0176" title="StettlerC , WandelS , AllemannS , KastratiA , MoriceMC , SchömigA , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet2007;370(9591):937-48. [PMID: 17869634]">Stettler 2007</a>), while one compared only sirolimus stents with bare‐metal stents (<a href="./references#CD012481-bbs2-0126" title="KastratiA , MehilliJ , PacheJ , KaiserC , ValgimigliM , KelbaekH , et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine2007;356(10):1030-9. [PMID: 17296823]">Kastrati 2007</a>). All reviews found no statistically significant difference between drug‐eluting stents and bare‐metal stents on all‐cause mortality. While <a href="./references#CD012481-bbs2-0176" title="StettlerC , WandelS , AllemannS , KastratiA , MoriceMC , SchömigA , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet2007;370(9591):937-48. [PMID: 17869634]">Stettler 2007</a> found a beneficial effect in favour of the drug‐eluting stents using sirolimus on myocardial infarction, they found no effect for drug‐eluting stents using paclitaxel. <a href="./references#CD012481-bbs2-0126" title="KastratiA , MehilliJ , PacheJ , KaiserC , ValgimigliM , KelbaekH , et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine2007;356(10):1030-9. [PMID: 17296823]">Kastrati 2007</a> and <a href="./references#CD012481-bbs2-0159" title="RoukozH , BavryAA , SarkeesML , MoodGR , KumbhaniDJ , RabbatMG , et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine2009;122(6):581. [PMID: 19486720]">Roukoz 2009</a> found no difference between drug‐eluting stents versus bare‐metal stents on myocardial infarction. All three reviews found a beneficial effect favouring drug‐eluting stents on target vessel revascularisation (<a href="./references#CD012481-bbs2-0126" title="KastratiA , MehilliJ , PacheJ , KaiserC , ValgimigliM , KelbaekH , et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine2007;356(10):1030-9. [PMID: 17296823]">Kastrati 2007</a>; <a href="./references#CD012481-bbs2-0159" title="RoukozH , BavryAA , SarkeesML , MoodGR , KumbhaniDJ , RabbatMG , et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine2009;122(6):581. [PMID: 19486720]">Roukoz 2009</a>; <a href="./references#CD012481-bbs2-0176" title="StettlerC , WandelS , AllemannS , KastratiA , MoriceMC , SchömigA , et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet2007;370(9591):937-48. [PMID: 17869634]">Stettler 2007</a>). </p> <section id="CD012481-sec-0015"> <h4 class="title">Current guidelines on drug‐eluting stents versus bare‐metal stents for acute coronary syndrome </h4> <p>The 2011 American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions guideline recommends drug‐eluting stents as a useful alternative to bare‐metal stents to prevent restenosis in cases where there is an increased risk of restenosis, and the patient is likely to be able to tolerate and comply with prolonged dual antiplatelet therapy (so‐called evidence A for STEMI, evidence C for NSTEMI/unstable angina pectoris; evidence levels are explained in the glossary in <a href="./appendices#CD012481-sec-0179">Appendix 1</a>) (<a href="./references#CD012481-bbs2-0133" title="LevineGN , BatesER , BlankenshipJC , BaileySR , BittlJA , CercekB , et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation2011;124(23):2574-609. [PMID: 22064598]">Levine 2011</a>). The clinical situations associated with increased risk of restenosis are left main disease, small vessels, in‐stent restenosis, bifurcations, diabetes, long lesions, multiple lesions, and saphenous vein grafts (<a href="./references#CD012481-bbs2-0133" title="LevineGN , BatesER , BlankenshipJC , BaileySR , BittlJA , CercekB , et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation2011;124(23):2574-609. [PMID: 22064598]">Levine 2011</a>; <a href="./references#CD012481-bbs2-0134" title="LevineGN , BatesER , BlankenshipJC , BaileySR , BittlJA , CercekB , et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Journal of the American College of Cardiology2016;67(10):1235-50.">Levine 2016</a>). The guideline also states that bare‐metal stents should be used in people with a high risk of bleeding; inability to comply with one year of dual antiplatelet therapy; or anticipated invasive or surgical procedures in the next year, which the 2013 American College of Cardiology Foundation/American Heart Association Guideline for the Management of ST‐Elevation Myocardial Infarction also recommends (<a href="./references#CD012481-bbs2-0069" title="American College of Emergency Physicians (ACEP), Society for Cardiovascular Angiography and Interventions, O'GaraPT , KushnerFG , AscheimDD , Casey DE Jr, ChungMK , deLemosJA , et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2013;61(4):e78-140.">ACEP 2013</a>; <a href="./references#CD012481-bbs2-0133" title="LevineGN , BatesER , BlankenshipJC , BaileySR , BittlJA , CercekB , et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation2011;124(23):2574-609. [PMID: 22064598]">Levine 2011</a>). </p> <p>The National Institute for Health and Care Excellence (NICE) has assessed the effects and cost‐effectiveness of drug‐eluting stents compared with bare‐metal stents (<a href="./references#CD012481-bbs2-0147" title="NICE (National Institute for Health and Care Excellence). Drug-eluting stents for the treatment of coronary artery disease. www.nice.org.uk/guidance/ta152?unlid=1066690929201610722145 (accessed prior to 12 February 2016).">NICE 2008</a>). NICE recommends drug‐eluting stents in people where the target artery for treatment has less than a 3 mm calibre or the lesion is longer than 15 mm, and the price difference between drug‐eluting stents and bare‐metal stents is no more than GBP 300. </p> <p>This review is an update of the 2010 Cochrane review mentioned above (<a href="./references#CD012481-bbs2-0101" title="GreenhalghJ , HockenhullJ , RaoN , DundarY , DicksonRC , BagustA . Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD004587. [DOI: 10.1002/14651858.CD004587.pub3]">Greenhalgh 2010</a>), which has now been divided into a review including acute coronary syndrome participants and a review including stable ischaemic heart disease participants. With the present review we planned to do the following: </p> <p> <ol id="CD012481-list-0006"> <li> <p>take full account of the risk of systematic errors ('bias'), design errors, and risks of random errors ('play of chance') (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>; <a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>; <a href="./references#CD012481-bbs2-0127" title="KeusF , WetterslevJ , GluudC , vanLaarhovenCJ . Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology2010;10:90.">Keus 2010</a>; <a href="./references#CD012481-bbs2-0187" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/tsa_manual.pdf (accessed 15 May 2015).">Thorlund 2011</a>; <a href="./references#CD012481-bbs2-0192" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>); </p> </li> <li> <p>include trials irrespective of outcome, follow‐up duration, and number of participants;</p> </li> <li> <p>assess outcomes at several time points and take into account the variability of the follow‐up period; and </p> </li> <li> <p>include all types of drug‐eluting stents, including polymer‐free stents and bioresorbable stents. </p> </li> </ol> </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012481-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012481-sec-0016"></div> <p>To assess the benefits and harms of drug‐eluting stents versus bare‐metal stents in people with acute coronary syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012481-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012481-sec-0017"></div> <section id="CD012481-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012481-sec-0019"> <h4 class="title">Types of studies</h4> <p>We searched for randomised clinical trials (both individual and cluster‐randomised trials) irrespective of publication type, publication status, publication date, and language. </p> </section> <section id="CD012481-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included participants of any age with a diagnosis of acute coronary syndrome (according to the definition of the trialists). </p> </section> <section id="CD012481-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included any type of drug‐eluting stents, including bioresorbable stents and polymer‐free drug‐eluting stents. </p> <p>We accepted any type of medical therapy as a co‐intervention to percutaneous coronary intervention. </p> <p>We included any type of bare‐metal stent as a control intervention.</p> </section> <section id="CD012481-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012481-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012481-list-0007"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events, defined as any untoward medical occurrence that resulted in death, was life‐threatening, was persistent, or led to significant disability, prolonged hospitalisation, or any medical event that had jeopardised the participant or required intervention to prevent it (<a href="./references#CD012481-bbs2-0121" title="International Conference on Harmonisation Expert Working Group (ICH-EWG). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice in CFR &amp; ICH Guidelines. Vol. 1. Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>). </p> </li> <li> <p>Major cardiovascular event, defined as a composite outcome consisting of cardiovascular mortality and myocardial infarction. </p> </li> <li> <p>Quality of life measured on any valid scale, such as the Seattle Angina Questionnaire or 36‐Item Short Form Health Survey (SF‐36) (<a href="./references#CD012481-bbs2-0191" title="Ware JE Jr, SherbourneCD . The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83.">Ware 1992</a>; <a href="./references#CD012481-bbs2-0199" title="WyrwichKW , SpertusJA , KroenkeK , TierneyWM , BabuAN , WolinskyFD , Heart Disease Expert Panel. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. American Heart Journal2004;147(4):615-22.">Wyrwich 2004</a>). </p> </li> </ol> </p> </section> <section id="CD012481-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012481-list-0008"> <li> <p>Cardiovascular mortality (defined by the trialists).</p> </li> <li> <p>Myocardial infarction (defined by the trialists).</p> </li> <li> <p>Angina on a continuous scale, such as 'angina stability' and 'angina frequency' used in the Seattle Angina Questionnaire (<a href="./references#CD012481-bbs2-0199" title="WyrwichKW , SpertusJA , KroenkeK , TierneyWM , BabuAN , WolinskyFD , Heart Disease Expert Panel. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. American Heart Journal2004;147(4):615-22.">Wyrwich 2004</a>). </p> </li> </ol> </p> </section> <section id="CD012481-sec-0025"> <h5 class="title">Exploratory outcomes</h5> <p> <ol id="CD012481-list-0009"> <li> <p>Stent thrombosis.</p> </li> <li> <p>Target vessel revascularisation (defined by the trialists). In general, target vessel revascularisation is any repeat percutaneous intervention or surgical bypass of any segment of the target vessel (<a href="./references#CD012481-bbs2-0110" title="HicksKA , HungJHM , MahaffeyKW , MehranR , NissenSE , StockbridgeNL , et al. Standardized definitions for end point events in cardiovascular trials. www.clinpage.com/images/uploads/endpoint-defs_11-16-2010.pdf (accessed 24 June 2016).">Hicks 2010</a>). </p> </li> </ol> </p> <p>We conducted meta‐analyses when possible of all dichotomous and continuous outcomes at the following two time points: </p> <p> <ul id="CD012481-list-0010"> <li> <p>outcomes assessed at maximal follow‐up (the time point of primary interest); and</p> </li> <li> <p>outcomes assessed at one month.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012481-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012481-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases:</p> <p> <ul id="CD012481-list-0011"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2017, Issue 1 of 12), 18 January 2017; </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily, and MEDLINE (Ovid, 1946 to 18 January 2017); </p> </li> <li> <p>Embase (Ovid, 1980 to 2017 week 3), 18 January 2017;</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Sciences Literature) (Bireme, 1982 to 19 January 2017); </p> </li> <li> <p>SCI‐EXPANDED (Thomson Reuters, 1900 to 19 January 2017);</p> </li> <li> <p>BIOSIS Web of Science (Thomson Reuters, 1926 to 19 January 2017).</p> </li> </ul> </p> <p>We adapted the search strategy for MEDLINE Ovid to the other databases (<a href="./appendices#CD012481-sec-0180">Appendix 2</a>). We applied the Cochrane sensitivity‐maximising randomised controlled trial filter to MEDLINE Ovid, adaptations of which were applied to the other databases, except CENTRAL and LILACS (<a href="./references#CD012481-bbs2-0131" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). We searched all databases from their inception and imposed no restriction on language of publication. </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, searched on 30 March 2017), the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.apps.who.int/trialsearch" target="_blank">www.apps.who.int/trialsearch</a>, searched on 31 March 2017), European Medicines Agency (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>, searched on 3 April 2017), and the US Food and Drug Administration (<a href="http://www.fda.gov/" target="_blank">www.fda.gov</a>, searched on 4 April 2017). We also searched <a href="http://scholar.google.dk/" target="_blank">Google Scholar</a> manually for trials not found in the preliminary search (<a href="./references#CD012481-bbs2-0131" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). We adapted the preliminary search strategy for MEDLINE (Ovid) for use in these databases. </p> <p>We also searched the websites of the following pharmaceutical companies for ongoing or unpublished trials: Johnson &amp; Johnson (<a href="https://www.jnj.com/about-jnj" target="_blank">www.jnj.com/about-jnj</a>, searched on 30 March 2017), Medtronic (<a href="http://www.medtronic.com/us-en/index.html" target="_blank">www.medtronic.com/us-en/index.html</a>, searched on 30 March 2017), Boston Scientific (<a href="https://www.bostonscientific.com/en-US/Home.html" target="_blank">www.bostonscientific.com/en-US/Home.html</a>, searched on 30 March 2017), and Abbott (<a href="http://www.abbott.com/" target="_blank">www.abbott.com/</a>, searched 30 March 2017). </p> </section> <section id="CD012481-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We identified additional trials from the reference lists of review articles and included trials. </p> </section> </section> <section id="CD012481-sec-0029"> <h3 class="title" id="CD012481-sec-0029">Data collection and analysis</h3> <p>We performed the review following the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We conducted the analyses using Review Manager 5 (<a href="./references#CD012481-bbs2-0155" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), Stata 14 (<a href="./references#CD012481-bbs2-0174" title="Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.">Stata 2015</a>), and Trial Sequential Analysis (<a href="./references#CD012481-bbs2-0083" title="Trial Sequential Analysis (TSA) (www.ctu.dk/tsa). Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research. Copenhagen, Denmark, 2011.">CTU 2011</a>). </p> <section id="CD012481-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JF and EEN) independently screened titles and abstracts of all of the potentially eligible trials for inclusion. We coded all of these studies as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. In case of disagreement, we asked a third review author to arbitrate (JCJ). We retrieved the full‐text trial reports/publications, and two review authors (JF and EEN) independently screened the full texts and identified trials for inclusion. We reported reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion. We identified and excluded duplicates and collated multiple reports of the same trial so that each trial, rather than each report, was the unit of interest in this review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' tables. </p> </section> <section id="CD012481-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that we had piloted on three trials in the review to collect trial characteristics and outcome data. Two review authors (JF and EEN) independently extracted all trial characteristics from the included trials. In case of disagreement, we asked a third review author to arbitrate (JCJ). We extracted the following trial characteristics. </p> <p> <ol id="CD012481-list-0012"> <li> <p>Methods: duration of the trial, details of any 'run‐in' period, and date of publication.</p> </li> <li> <p>Participants: number randomised, number analysed, number lost to follow up/withdrawn, mean age, sex, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: trial funding and notable conflicts of interest of the trial authors.</p> </li> </ol> </p> <p>Two review authors (JF and EEN) independently extracted outcome data from the included studies. Any disagreements were resolved by consensus or by involving a third review author (JCJ). One review author (JF) transferred the data into the Review Manager 5 file (<a href="./references#CD012481-bbs2-0155" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the review with the study reports. A second review author (EEN) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD012481-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JF and EEN) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Any disagreements were resolved by discussion or by involving a third review author (JCJ). We assessed the risk of bias according to the random sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias. These 'risk of bias' domains enable the classification of randomised trials with an overall bias assessment at low or high risk of bias. Trials with one domain at either high or unclear risk of bias are considered at overall high risk of bias as previous meta‐epidemiological studies demonstrate that these two categories do not differ in their overestimation of benefits and underestimation of harms (<a href="./references#CD012481-bbs2-0100" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD012481-bbs2-0129" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012481-bbs2-0136" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012481-bbs2-0137" title="LundhA , BeroL . The ties that bind. BMJ2017;356:j176.">Lundh 2017</a>; <a href="./references#CD012481-bbs2-0144" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD012481-bbs2-0162" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012</a>; <a href="./references#CD012481-bbs2-0163" title="SavovićJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD012481-bbs2-0165" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD012481-bbs2-0198" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). For additional details on how we assessed the risk of bias, see <a href="./appendices#CD012481-sec-0181">Appendix 3</a>. We assessed the risk of bias at both trial level and outcome level. </p> </section> <section id="CD012481-sec-0033"> <h4 class="title">Assessment of bias in conducting the review</h4> <p>We conducted the review according to the published protocol and have reported any deviations from it in the <a href="#CD012481-sec-0197">Differences between protocol and review</a> section of this review. </p> </section> <section id="CD012481-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012481-sec-0035"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes. </p> </section> <section id="CD012481-sec-0036"> <h5 class="title">Continuous outcomes</h5> <p>We had planned to use end scores in our analyses if both end scores and change scores were reported. If only change scores were reported, we would use these, but no trials reported any continuous outcomes. We planned to calculate mean differences (MD) and standardised mean differences (SMD) with 95% CIs for continuous outcomes, as well as Trial Sequential Analysis‐adjusted CIs. We planned to use the SMD when all trials assessed the same outcome but measured it in a variety of ways, for example with different scales (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> </section> <section id="CD012481-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>Where multiple trial arms were reported in a single trial, we only included the relevant arms. In the case of a trial with two relevant experimental arms (<a href="./references#CD012481-bbs2-0019" title="Di LorenzoE , De LucaG , SauroR , VarricchioA , CapassoM , LanzilloT , et al. The PASEO (paclitaxel- or sirolimus-eluting stent versus bare metal stent in primary angioplasty) randomized trial. JACC: Cardiovascular Interventions2009;2(6):515-23. Di LorenzoE , SauroR , VarricchioA , CapassoM , LanzilloT , ManganelliF , et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the paclitaxel or sirolimus-eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial. American Heart Journal2009;158(4):e43-50. ">PASEO 2009a</a>; <a href="./references#CD012481-bbs2-0020" title="">PASEO 2009b</a>), we included the two arms as different comparisons and halved the control group to avoid double‐counting. </p> </section> <section id="CD012481-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to obtain any missing data.</p> <section id="CD012481-sec-0039"> <h5 class="title">Dichotomous outcomes</h5> <p>We did not impute missing values for any outcomes in our primary analysis. We imputed data in two of our sensitivity analyses (see <a href="#CD012481-sec-0052">Sensitivity analysis</a>). </p> </section> <section id="CD012481-sec-0040"> <h5 class="title">Continuous outcomes</h5> <p>We did not impute missing values for any outcomes in our primary analysis. We planned to impute data in our sensitivity analysis for dichotomous and continuous outcomes (see <a href="#CD012481-sec-0052">Sensitivity analysis</a>). </p> <p>If studies did not report standard deviations (SD), we planned to calculate them using data from the trial where possible. </p> </section> </section> <section id="CD012481-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We primarily investigated forest plots to visually assess for any sign of heterogeneity. We additionally assessed the presence of statistical heterogeneity by Chi<sup>2</sup> test (threshold P &lt; 0.10) and measured the quantities of heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD012481-bbs2-0111" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD012481-bbs2-0112" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We followed the recommendations for thresholds in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>): </p> <p> <ul id="CD012481-list-0013"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We investigated possible heterogeneity through subgroup analyses. Ultimately, we performed meta‐analyses of our outcomes (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD012481-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias and other reporting biases by visual inspection of funnel plots for our primary outcomes if we included at least 10 trials (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Using the asymmetry of the funnel plot, we assessed the risk of bias. To attempt to correct for the impact of any reporting bias, we used the 'trim and fill' method (<a href="./references#CD012481-bbs2-0093" title="DuvalS , TweedieR . Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics2000;56:455-63.">Duval 2000</a>; <a href="./references#CD012481-bbs2-0184" title="TaylorSJ , TweedieRL . Practical estimates of the effect of publication bias in meta-analysis. Australian Epidemiologist1998;5:14-7.">Taylor 1998</a>). </p> <p>For dichotomous outcomes, we tested asymmetry with the Harbord test, <a href="./references#CD012481-bbs2-0107" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [PMID: 16345038]">Harbord 2006</a>, if Tau<sup>2</sup> was less than 0.1 and with the Rücker test, <a href="./references#CD012481-bbs2-0160" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine2008;27(5):746-63. [PMID: 17592831]">Rücker 2008</a>, if Tau<sup>2</sup> was more than 0.1. </p> </section> <section id="CD012481-sec-0043"> <h4 class="title">Data synthesis</h4> <section id="CD012481-sec-0044"> <h5 class="title">Meta‐analysis</h5> <p>We undertook this systematic review according to the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012481-bbs2-0113" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), according to <a href="./references#CD012481-bbs2-0127" title="KeusF , WetterslevJ , GluudC , vanLaarhovenCJ . Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology2010;10:90.">Keus 2010</a>, and according to the eight‐step assessment suggested by <a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>. We used the statistical software Review Manager 5, provided by Cochrane, to meta‐analyse data (<a href="./references#CD012481-bbs2-0155" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>We used Stata, <a href="./references#CD012481-bbs2-0174" title="Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.">Stata 2015</a>, in case of zero‐event trials where Review Manager 5's zero‐event handling (replacing zero with a constant of 0.5) was not sufficient, for example in cases with a skewed number of participants between groups, we planned to handle this with reciprocal zero‐event handling according to <a href="./references#CD012481-bbs2-0182" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine2004;23(9):1351-75. [PMID: 15116347]">Sweeting 2004</a>. Additionally, we planned on using <a href="./references#CD012481-bbs2-0174" title="Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.">Stata 2015</a> in case we needed to undertake meta‐regression (post hoc). </p> <p>We used Trial Sequential Analysis to assess and control the risk of random error (see below). If a meta‐analysis did not reach the required information size, we presented Trial Sequential Analysis‐adjusted confidence intervals to account for the lack of information. </p> <p>We included all studies in our initial analyses and planned to conduct a sensitivity analysis of trials at low risk of bias, however no such trials were found. If the results were similar, we planned to base our primary conclusions on the overall analysis. If results differed, we planned to base our primary conclusions on trials at low risk of bias. </p> </section> <section id="CD012481-sec-0045"> <h5 class="title">Trial Sequential Analysis</h5> <p>Cumulative meta‐analyses are at risk of producing random errors due to sparse data and multiple testing of accumulating data (<a href="./references#CD012481-bbs2-0075" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9.">Brok 2008</a>; <a href="./references#CD012481-bbs2-0076" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive. Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98.">Brok 2009</a>; <a href="./references#CD012481-bbs2-0114" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random-effects meta-analysis. Statistics in Medicine2011;30(9):903-21. [PMID: 21472757]">Higgins 2011a</a>; <a href="./references#CD012481-bbs2-0151" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials1997;18(6):580-93; discussion 661-6. [PMID: 9408720]">Pogue 1997</a>; <a href="./references#CD012481-bbs2-0186" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?International Journal of Epidemiology2009;38(1):276-86.">Thorlund 2009</a>; <a href="./references#CD012481-bbs2-0192" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>); Trial Sequential Analysis can be applied to control this risk (<a href="./references#CD012481-bbs2-0083" title="Trial Sequential Analysis (TSA) (www.ctu.dk/tsa). Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research. Copenhagen, Denmark, 2011.">CTU 2011</a>; <a href="./references#CD012481-bbs2-0123" title="JacksonD , TurnerR . Power analysis for random-effects meta-analysis. Research Synthesis Methods 2017 Apr 4 [Epub ahead of print]. [DOI: 10.1002/jrsm.1240] [PMID: 28378395]">Jackson 2017</a>; <a href="./references#CD012481-bbs2-0187" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/tsa_manual.pdf (accessed 15 May 2015).">Thorlund 2011</a>; <a href="./references#CD012481-bbs2-0194" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). The required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) can be calculated in order to minimise random errors (<a href="./references#CD012481-bbs2-0192" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012481-bbs2-0193" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). The required information size takes into account the event proportion in the control group, the assumption of a plausible risk ratio reduction, and the heterogeneity of the meta‐analysis (<a href="./references#CD012481-bbs2-0189" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS ONE2013;8(3):e59202. [PMID: 23544056]">Turner 2013</a>; <a href="./references#CD012481-bbs2-0192" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012481-bbs2-0193" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>; <a href="./references#CD012481-bbs2-0194" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). Trial Sequential Analysis enables testing for significance each time a meta‐analysis includes a new trial. On the basis of the required information size, trial sequential monitoring boundaries can be constructed, enabling the determination of the statistical inference concerning cumulative meta‐analysis that has not yet reached the required information size (<a href="./references#CD012481-bbs2-0192" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012481-bbs2-0194" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). </p> <p>Firm evidence for benefit or harms may be established if the trial sequential monitoring boundary is crossed before reaching the required information size, in which case further trials may turn out to be superfluous. In contrast, if the boundaries for benefit or harm are not surpassed, it may be established that it is necessary to continue with further trials before a certain intervention effect can be detected or rejected. Firm evidence for lack of the postulated intervention effect, which occurs when the cumulative Z‐score crosses the trial sequential monitoring boundaries for futility, can also be assessed with Trial Sequential Analysis. </p> <p>To control the risks of random error, we used relatively conservative estimations of the anticipated intervention effect estimates (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). Large anticipated intervention effects lead to small required information sizes, and the thresholds for significance will be too lenient (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> <p>We analysed all primary and secondary outcomes with Trial Sequential Analysis. We used the following assumptions. </p> <section id="CD012481-sec-0046"> <h6 class="title">Primary outcomes</h6> <p>We estimated the diversity‐adjusted required information size based on the proportion of participants with an outcome in the control group (<a href="./references#CD012481-bbs2-0193" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). We used a risk of a type I error of 2% (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>), a risk of a type II error of 20%, and the diversity suggested by the trials in the meta‐analysis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We used a risk of a type I error of 2% due to us including four primary outcomes, hence adjusting our type I error accordingly (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We chose a risk of a type II error of 20% based primarily on tradition; it could be argued this value should be lower (<a href="./references#CD012481-bbs2-0079" title='CastelliniG , NielsenEE , GluudC . Comment on: "Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews". Clinical Pharmacology and Therapeutics 2016 Oct 11 [Epub ahead of print]. [DOI: 10.1002/cpt.536]'>Castellini 2016</a>). </p> <p>As anticipated intervention effects we used the following risk ratio reductions (RRR) because they seemed to be the maximum realistic intervention effect estimates based on former studies, trials, and meta‐analyses. </p> <p> <ul id="CD012481-list-0014"> <li> <p>All‐cause mortality: RRR of 10% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> <li> <p>Serious adverse events: RRR of 10%.</p> </li> <li> <p>Major cardiovascular event defined as a composite outcome consisting of cardiovascular mortality and myocardial infarction: RRR of 10% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> <li> <p>Quality of life measured on any valid scale, such as the Seattle Angina Questionnaire or SF‐36: we planned to use the observed SD, a clinically relevant mean difference equal to SD/2. </p> </li> </ul> </p> </section> <section id="CD012481-sec-0047"> <h6 class="title">Secondary outcomes</h6> <p>We estimated the diversity‐adjusted required information size based on the proportion of participants with an outcome in the control group (<a href="./references#CD012481-bbs2-0193" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). We used a risk of a type I error of 2.5% (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>), a risk of a type II error of 20%, and the diversity suggested by the trials in the meta‐analysis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We used a risk of a type I error of 2.5% due to us including three secondary outcomes, hence adjusting our type I error accordingly (<a href="./references#CD012481-bbs2-0125" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. The Cochrane Database of Systematic Reviews2016;3:ED000111. [DOI: 10.1002/14651858.ED000111]">Jakobsen 2016</a>). We chose a risk of a type II error of 20% based primarily on tradition; it could be argued this value should be lower (<a href="./references#CD012481-bbs2-0079" title='CastelliniG , NielsenEE , GluudC . Comment on: "Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews". Clinical Pharmacology and Therapeutics 2016 Oct 11 [Epub ahead of print]. [DOI: 10.1002/cpt.536]'>Castellini 2016</a>). </p> <p>As anticipated intervention effects for the secondary outcomes in the Trial Sequential Analysis, we used the following RRRs because we assumed that these intervention effects were realistic based on former studies, trials, and meta‐analyses as cited below. </p> <p> <ul id="CD012481-list-0015"> <li> <p>Myocardial infarction: RRR of 10% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> <li> <p>Cardiovascular mortality: RRR of 10% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> <li> <p>Angina (continuous outcome): the observed SD, a clinically relevant mean difference equal to SD/2. </p> </li> </ul> </p> </section> <section id="CD012481-sec-0048"> <h6 class="title">Exploratory outcomes</h6> <p>We estimated the diversity‐adjusted required information size based on the proportion of participants with an outcome in the control group (<a href="./references#CD012481-bbs2-0193" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>). We used a risk of a type I error of 3.33% (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>), a risk of a type II error of 20%, and the diversity suggested by the trials in the meta‐analysis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We used a risk of a type I error of 3.33% due to us including two exploratory outcomes, hence adjusting our type I error accordingly (<a href="./references#CD012481-bbs2-0125" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. The Cochrane Database of Systematic Reviews2016;3:ED000111. [DOI: 10.1002/14651858.ED000111]">Jakobsen 2016</a>). We chose a risk of a type II error of 20% based primarily on tradition; it could be argued this value should be lower (<a href="./references#CD012481-bbs2-0079" title='CastelliniG , NielsenEE , GluudC . Comment on: "Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews". Clinical Pharmacology and Therapeutics 2016 Oct 11 [Epub ahead of print]. [DOI: 10.1002/cpt.536]'>Castellini 2016</a>). </p> <p>As anticipated intervention effects for the exploratory outcomes in the Trial Sequential Analysis, we used the following RRRs because we assumed that these intervention effects were realistic based on former studies, trials, and meta‐analyses as cited below. </p> <p> <ul id="CD012481-list-0016"> <li> <p>Stent thrombosis: RRR of 10% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> <li> <p>Target vessel revascularisation: RRR of 30% (<a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a>; <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a>). </p> </li> </ul> </p> <p>As supplementary Trial Sequential Analysis, we planned to use the limit of the confidence interval closest to zero effect as the anticipated intervention effect for all trial sequential analyses (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </section> </section> <section id="CD012481-sec-0049"> <h5 class="title">Assessment of significance</h5> <p>We assessed our intervention effects with both random‐effects meta‐analyses, <a href="./references#CD012481-bbs2-0090" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88. [PMID: 3802833]">DerSimonian 1986</a>, and fixed‐effect meta‐analyses, <a href="./references#CD012481-bbs2-0089" title="DemetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50. [PMID: 3616287]">Demets 1987</a>, using the more conservative point estimate, that is the estimate closest to zero effect, of the two (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). If the two estimates were equal, we used the estimate with the widest confidence interval. We had four primary outcomes and three secondary outcomes, and therefore considered a P value less than 2% as significant for the primary outcomes and a P value less than 2.5% as significant for the secondary outcomes (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>; <a href="./references#CD012481-bbs2-0125" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. The Cochrane Database of Systematic Reviews2016;3:ED000111. [DOI: 10.1002/14651858.ED000111]">Jakobsen 2016</a>). We used the eight‐step procedure to assess if the thresholds for significance were crossed or not (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </section> </section> <section id="CD012481-sec-0050"> <h4 class="title">'Summary of findings' tables</h4> <p>We used the GRADE approach to assess the quality of the body of evidence associated with each of the primary outcomes (all‐cause mortality, serious adverse events, major cardiovascular events, and quality of life) and secondary outcomes (cardiovascular mortality, myocardial infarction, and angina) in our review (<a href="./references#CD012481-bbs2-0105" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>), constructing 'Summary of findings' tables using GRADEpro software (www.gradepro.org). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality measure of a body of evidence considers within‐study risk of bias, directness of the evidence, heterogeneity of the data, precision of effect estimates, and risk of publication bias (<a href="./references#CD012481-bbs2-0105" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). We assessed the precision of the effect estimates according to Jakobsen and colleagues (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We included all studies in our primary analyses, as we found no trials at low risk of bias or at low risk of bias in all domains other than 'blinding of participants and personnel' (<a href="./references#CD012481-bbs2-0100" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD012481-bbs2-0129" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012481-bbs2-0136" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012481-bbs2-0144" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD012481-bbs2-0162" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012</a>; <a href="./references#CD012481-bbs2-0165" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD012481-bbs2-0198" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). </p> </section> <section id="CD012481-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses.</p> <p> <ul id="CD012481-list-0017"> <li> <p>Type of drug‐eluting stents used:</p> <ul id="CD012481-list-0018"> <li> <p>paclitaxel‐eluting stents;</p> </li> <li> <p>sirolimus‐eluting stents;</p> </li> <li> <p>zotarolimus‐eluting stents;</p> </li> <li> <p>everolimus‐eluting stents;</p> </li> <li> <p>bioresorbable stents;</p> </li> <li> <p>polymer‐free drug‐eluting stents; and</p> </li> <li> <p>mixed drug‐eluting stents.</p> </li> </ul> </li> <li> <p>Unstable angina pectoris/non‐ST‐segment elevation myocardial infarction participants compared with ST‐segment elevation myocardial infarction participants. </p> </li> <li> <p>Length of maximum follow‐up:</p> <ul id="CD012481-list-0019"> <li> <p>less than or equal to six months;</p> </li> <li> <p>between six months and 12 months;</p> </li> <li> <p>between one year and three years; and</p> </li> <li> <p>more than or equal to three years.</p> </li> </ul> </li> <li> <p>Comparison of the effect of drug‐eluting stents versus bare‐metal stents between trials with different clinical trial registration status: </p> <ul id="CD012481-list-0020"> <li> <p>pre‐registration;</p> </li> <li> <p>postregistration; and</p> </li> <li> <p>no registration.</p> </li> </ul> </li> </ul> </p> <p>We only used the primary outcomes in our subgroup analyses.</p> <p>We used the formal test for subgroup differences in Review Manager 5 (<a href="./references#CD012481-bbs2-0155" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>We did not perform the following subgroup analyses due to lack of data.</p> <p> <ul id="CD012481-list-0021"> <li> <p>Participants with diabetes compared with participants without diabetes.</p> </li> <li> <p>Participants with high risk of bleeding (as defined by trialists) compared with participants without high risk of bleeding. </p> </li> <li> <p>Age of participants:</p> <ul id="CD012481-list-0022"> <li> <p>age 0 to 18 years;</p> </li> <li> <p>age 19 to 75 years; and</p> </li> <li> <p>age 76 years or above.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD012481-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to assess the potential impact of bias by performing a sensitivity analysis where we excluded trials at high risk of bias. However, we found no trials at low risk of bias. </p> <p>As a secondary sensitivity analysis, we planned to only include trials with low risk of bias in all domains except 'blinding of participants and personnel', as we did not expect to find any trials at low risk of bias in this domain. However, we found no such trial. We thoroughly discussed the limitations of trials at high risk of bias in the <a href="#CD012481-sec-0160">Quality of the evidence</a>. </p> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed the two following analyses. </p> <p> <ol id="CD012481-list-0023"> <li> <p>'Best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group survived, had no serious adverse event, had no major cardiovascular event, had no stent thrombosis, and had no target vessel revascularisation. We assumed that they also had a beneficial event with regard to quality of life and angina, defined as the group mean plus both one and two SDs of the group mean (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We assumed that all of those with missing outcomes in the control group died, had a serious adverse event, had a major cardiovascular event, had stent thrombosis, and had target vessel revascularisation. We assumed that they also had a harmful event with regard to quality of life and angina, defined as the group mean plus both one and two SDs of the group mean (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </li> <li> <p>'Worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group died, had a serious adverse event, had a major cardiovascular event, had stent thrombosis, and had target vessel revascularisation. We assumed that they also had a harmful event with regard to quality of life and angina, defined as the group mean plus both one and two SDs of the group mean (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We assumed that all of those with missing outcomes in the control group survived, had no serious adverse event, had no major cardiovascular event, had no stent thrombosis, and had no target vessel revascularisation. We assumed that they also had a beneficial event with regard to quality of life and angina, defined as the group mean plus both one and two SDs of the group mean (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </li> </ol> </p> <p>We presented results from both scenarios.</p> <p>To assess the potential impact of missing SDs for continuous outcomes, we planned to perform the following sensitivity analyses. </p> <p> <ul id="CD012481-list-0024"> <li> <p>Where SDs were missing and not possible to calculate, we would impute SDs from trials with similar populations and low risk of bias. </p> </li> <li> <p>If we found no such trials, we would impute SDs from trials with a similar population. As the final option, we would impute SDs from all trials. </p> </li> </ul> </p> <p>However, as we included no trials reporting data on continuous outcomes, we did not perform the above sensitivity analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012481-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012481-sec-0053"></div> <section id="CD012481-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD012481-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified a total of 76,576 potentially relevant references through searching the CENTRAL (Cochrane Library) (n = 8778), MEDLINE (n = 21,652), Embase (n = 14,916), SCI‐EXPANDED (n = 19,920), BIOSIS (n = 10,657), and LILACS (n = 653) from inception to January 2017. The search strategy is presented in <a href="./appendices#CD012481-sec-0180">Appendix 2</a>. Additionally, we found 18 trials by searching Google Scholar, ClinicalTrials.gov, and references identified through previous meta‐analyses and randomised clinical trials. We excluded 34,514 reference duplicates. Accordingly, we screened 42,080 records and excluded 41,985 references based on titles and abstracts. We assessed 95 full‐text articles for eligibility. Of these, we excluded 27 references reporting on 25 trials based on our inclusion and exclusion criteria. We have provided reasons for exclusion the <a href="./references#CD012481-sec-0200" title="">Characteristics of excluded studies</a> table. Fourteen trials/15 comparisons reported on a mix of acute coronary syndrome participants and stable angina participants and are awaiting classification (<a href="./references#CD012481-sec-0201" title="">Characteristics of studies awaiting classification</a>) (<a href="./references#CD012481-bbs2-0053" title="KaiserC , Brunner-La RoccaH , BuserP , BonettiP , OsswaldS , LinkaA , et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet2005;366:921-9. ">BASKET 2005a</a>; <a href="./references#CD012481-bbs2-0054" title="">BASKET 2005b</a>; <a href="./references#CD012481-bbs2-0055" title="KaiserC , GalatiusS , ErneP , EberliF , AlberH , RickliH , et al. Drug-eluting versus bare-metal stents in large coronary arteries. New England Journal of Medicine2010;363(24):2310-9. [DOI: 10.1056/NEJMoa1009406] [PMID: 21080780]">BASKET‐PROVE I 2010</a>; <a href="./references#CD012481-bbs2-0056" title="KaiserC , GalatiusS , JegerR , GilgenN , Skov JensenJ , NaberCK , et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation2015;131(1):74-81. [DOI: 10.1161/CIRCULATIONAHA.114.013520] [PMID: 25411159]">BASKET‐PROVE II 2015</a>; <a href="./references#CD012481-bbs2-0057" title="IschingerT . European study of Axxion and Glycocalix long-term evaluation. Herz2006;31:596. ">EAGLE 2006</a>; <a href="./references#CD012481-bbs2-0058" title="ErglisA , NarbuteI , KumsarsI , JegereS , MintaleI , ZakkeI , et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. Journal of the American College of Cardiology2007;50(6):491-7. ">Erglis 2007</a>; <a href="./references#CD012481-bbs2-0059" title="CostaRA , LanskyAJ , MintzGS , MehranR , TsuchiyaY , NegoitaM , et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). American Journal of Cardiology2005;95(1):113–6. GrubeE , SonodaS , IkenoF , HondaY , KarS , ChanC , et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation2004;109:2168–71. ">FUTURE I 2004</a>; <a href="./references#CD012481-bbs2-0060" title="StorgerH , GrubeE , HofmannM , SchwartzF , HaaseJ . Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. Journal of Interventional Cardiology2004;17(6):387-90. ">FUTURE II 2004</a>; <a href="./references#CD012481-bbs2-0061" title="HanYL , WangSL , JingQM , YuHB , WangB , MaYY , et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chinese Medical Journal2007;120(7):552–6. ">Han 2007</a>; <a href="./references#CD012481-bbs2-0062" title="LiS , FuX , LiuJ , WuW , GuX , MaN , et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary small vessel lesions. American Journal of Cardiology2004;94(6A):218E. ">Li 2004</a>; <a href="./references#CD012481-bbs2-0063" title="BønaaKH , MannsverkJ , WisethR , AabergeL , MyrengY , NygårdO , et al. Drug-eluting or bare-metal stents for coronary artery disease. New England Journal of Medicine2016;375:1242-52. ">NORSTENT 2016</a>; <a href="./references#CD012481-bbs2-0064" title="ValgimigliM , CampoG , PercocoG , MontiM , FerrariF , TumscitzC , et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal2010;160(5):804-11. [PMID: 21095265]ValgimigliM , TebaldiM , BorghesiM , BranckxP , CampoG , TumscitzC , et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention. JACC: Cardiovascular Interventions2014;7(1):20-8. [PMID: 24332420]">PRODIGY 2014</a>; <a href="./references#CD012481-bbs2-0065" title="ArdissinoD , CavalliniC , BramucciE , IndolfiC , MarzocchiA , ManariA , et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA2004;292(22):2727-34. [PMID: 15585732]">SES‐SMART 2004</a>; <a href="./references#CD012481-bbs2-0066" title="deBelderA , dela Torre HernandezJM , Lopez-PalopR , O'KaneP , HernandezFH , StrangeJ , et al. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians. Journal of the American College of Cardiology2014;63(14):1371-5. [DOI: 10.1016/j.jacc.2013.10.053] [PMID: 24216285]">XIMA 2014</a>; <a href="./references#CD012481-bbs2-0067" title="ValgimigliM , PatialiakasA , ThuryA , ColangeloS , CampoG , TebaldiM , et al. Randomized comparison of zotarolimus-eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates study. American Heart Journal2013;166(5):831-8. [PMID: 24176438]ValgimigliM , PatialiakasA , ThuryA , McFaddenE , ColangeloS , CampoG , et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. Journal of the American College of Cardiology2015;65(8):805-15. [PMID: 25720624]">ZEUS 2015</a>). We tried but could not establish contact with the trial authors to obtain individual participant data. We therefore did not include these trials in the primary analyses, but only in our exploratory analyses. </p> <p>We included 51 publications reporting results of 25 trials (26 comparisons). The study flow chart is presented in <a href="#CD012481-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012481-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="study flow diagram." data-id="CD012481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>study flow diagram.</p> </div> </div> </div> </section> <section id="CD012481-sec-0056"> <h4 class="title">Included studies</h4> <p>We included 51 references reporting on 25 trials (26 comparisons) in our primary analyses comparing drug‐eluting stents versus bare‐metal stents. The trials were published between 2004 and 2016. The trials (which often took place in more than one country) were conducted at sites in 21 different countries: eight from Italy; eight from the Netherlands; five from Spain; three from Germany; three from the UK; three from Denmark; two each from Switzerland, Argentina, Austria, and Israel; and one each from Brazil, China, Croatia, Finland, France, Iran, Norway, Poland, Serbia, Sweden, and the USA. For further details on included studies please see <a href="./references#CD012481-sec-0199" title="">Characteristics of included studies</a>. </p> <p>At one‐month follow‐up (median one‐month follow‐up), 6/25 trials reported all‐cause mortality, 7/25 trials reported serious adverse events, 6/25 trials reported major cardiovascular events, 5/25 trials reported cardiovascular mortality, 6/25 trials reported myocardial infarction, 5/25 trials reported stent thrombosis, and 6/25 trials reported target vessel revascularisation. No trials reported quality of life or angina. </p> <p>At maximum follow‐up (median 12 months, range 1 to 72 months' follow‐up), 21/25 trials reported all‐cause mortality, 22/25 trials reported serious adverse events, 19/25 trials reported major cardiovascular events, 14/25 trials reported cardiovascular mortality, 18/25 trials reported myocardial infarction, 20/25 trials reported stent thrombosis, and 22/25 trials reported target vessel revascularisation. No trials reported quality of life or angina. Serious adverse events was not reported comprehensively and were limited to all‐cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and target vessel revascularisation. </p> <section id="CD012481-sec-0057"> <h5 class="title">Participants</h5> <p>The 25 included trials (26 comparisons) randomised a total of 12,503 participants with acute coronary syndrome. The number of participants in each trial ranged from 16 to 3006. The mean age was 60.4 years (range 55.9 years to 65.9 years) in the drug‐eluting stents group and 61.2 years (range 57.1 years to 64.6 years) in the bare‐metal stents group. The mean proportion of women was 21.1% in the drug‐eluting stents group and 31.3% in the bare‐metal stents group. In the drug‐eluting stents group 15.4% of participants had diabetes, whereas in the bare‐metal stents group 14.2% had diabetes. In both the drug‐eluting stents group and the bare‐metal stents group, 45% of participants had hypertension. In the drug‐eluting stents group 40.5% had hyperlipidaemia, whereas in the bare‐metal stents group 39.5% had hyperlipidaemia. The percentage of participants who had a previous myocardial infarction was 7.7% in the drug‐eluting stents group and 7.8% in the bare‐metal stents group. In the drug‐eluting stents group 6.6% had undergone a previous PCI, whereas in the bare‐metal stents group 5.7% had undergone a previous PCI. In the drug‐eluting stents group 2.3% had had a coronary bypass graft inserted, whereas in the bare‐metal stents group 1.9% had had a coronary bypass graft inserted. </p> <p>In 22 trials (23 comparisons), the participants presented with STEMI. In two trials, the participants presented with different types of acute coronary syndrome. In one trial (<a href="./references#CD012481-bbs2-0009" title="RemkesWS , BadingsEA , HermanidesRS , RasoulS , DambrinkJHE , KoopmansPC , et al. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. Open Heart2016;3(2):e000455. ">ELISA‐3 2016</a>), participants presented with NSTEMI. </p> <p>In the drug‐eluting stents group, 50.1% had a lesion in the left anterior descending artery, 48.6% a lesion in the right circumflex artery, and 17.4% in the left circumflex artery. Under 1% had a lesion in the left main artery, intermediate branch, or in a graft. In the bare‐metal stents group, 49.8% had a lesion in the left anterior descending artery, 49.3% a lesion in the right circumflex artery, and 18.6% in the left circumflex artery. Under 1% had a lesion in the left main artery, intermediate branch, or in a graft. </p> <p>In the drug‐eluting stents group, 62% of participants had one vessel disease and 38% had multivessel disease. In the bare‐metal stents group, 59% had one vessel disease and 41% had multivessel disease. In the drug‐eluting stents group, 62% of participants had a lesion with TIMI flow 0/1, 13.9% with TIMI 2, and 26.2% with TIMI 3. In the bare‐metal stents group, 61.6% had a lesion with TIMI flow 0/1, 13.9% with TIMI 2, and 26.3% with TIMI 3. Participants may have had a lesion in more than one vessel, hence the total of the above percentages is equal to more than 100%. </p> </section> <section id="CD012481-sec-0058"> <h5 class="title">Experimental intervention</h5> <p>We included 11 trials where the drug‐eluting stent was a sirolimus‐eluting stent (with seven of these being a Cypher sirolimus‐eluting stent) and eight trials (nine comparisons) where it was a paclitaxel‐eluting stent (with six trials using a Taxus stent, either Express, Liberte, or unspecified). Two trials used an everolimus‐eluting stent, one trial a Biolimus‐eluting stent, one trial a dexamethasone‐eluting stent, one trial a zotarolimus‐eluting stent, and one trial a mix of drug‐eluting stents (sirolimus‐, paclitaxel‐ and zotarolimus‐eluting stents). In one trial it was unclear what type of drug‐eluting stent was used. </p> <p>Successful PCI was performed in 95.2% of participants in the drug‐eluting stents group (reported by 16 trials). The average length of the drug‐eluting stent was 23.87 mm. The mean duration from onset of chest pain to PCI was 235.5 minutes (range 144 to 438 minutes) in the drug‐eluting stents group </p> </section> <section id="CD012481-sec-0059"> <h5 class="title">Control intervention</h5> <p>The bare‐metal stent used in three trials was an Express bare‐metal stent, two trials a Driver stent, one trial an Express2 stent, one trial a Gazelle stent, one trial a Genius MAGIC stent, one trial a Multi‐Link Vision cobalt chromium stent, one trial a Vision stent, one trial a BiodivYsio stent, one trial a BX stent, and one trial a Liberte stent. In 10 trials the bare‐metal stent used was not specified. One trial used a mix of different bare‐metal stents. </p> <p>Successful PCI was performed in 93.0% of participants in the bare‐metal stents group (reported by 16 trials). The average length of the bare‐metal stent was 22.29 mm. The mean duration from onset of chest pain to PCI was 242.2 minutes (range 164 to 426 minutes) in the bare‐metal stents group </p> </section> <section id="CD012481-sec-0060"> <h5 class="title">Co‐interventions</h5> <p>All 25 trials (26 comparisons) employed co‐interventions. In 22 of these trials the study was designed to deliver the co‐interventions similarly in the drug‐eluting stents group and the bare‐metal stents group. In two trials the co‐interventions were not specified, and in one trial the drug‐eluting stents group and the bare‐metal stents group received different co‐interventions (different length of antithrombotic therapy). Before or at the time of PCI, aspirin was given to 99.8% of participants in both groups in the 10 trials that reported this. Clopidogrel was given to 85.4% of participants in the drug‐eluting stents group and 84.6% of participants in the bare‐metal stents group in the 10 trials that reported this. Heparin was given to 88.9% of participants in the drug‐eluting stents group and 89.8% of participants in the bare‐metal stents group in the eight trials that reported this. Glycoprotein IIb/IIIa receptor blocker was given to 63.5% of participants in the drug‐eluting stents group and 61.4% of participants in the bare‐metal stents group in the nine trials that reported this. For further details see <a href="./references#CD012481-sec-0199" title="">Characteristics of included studies</a>. </p> <p>The post‐stent implantation therapy in 14 of the 25 trials was 80 mg to 100 mg of aspirin every day indefinitely. One trial administered 80 mg to 325 mg indefinitely; a second trial administered 250 mg for at least a year; and a third trial stated that participants received aspirin, but the dose was unclear. In eight trials it was unclear if the participants received aspirin in the months after stent implantation. </p> <p>In three trials clopidogrel was administered for a year at an unspecified dose. In two trials 75 mg clopidogrel was administered for three months; in nine trials 75 mg was administered for nine to 12 months; and in four trials 75 mg was administered for six months. In five trials it was unclear if participants received clopidogrel in the months after stent implantation. One trial administered 500 mg ticlopidine for six weeks. Another trial administered 60 mg of prasugrel or 75 mg of clopidogrel for one year. </p> </section> </section> <section id="CD012481-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Based on our inclusion and exclusion criteria, we excluded 27 publications on 25 trials after full‐text assessment. Seven trials did not assess drug‐eluting stents; four trials did not assess bare‐metal stents; one trial used a different medical intervention in the drug‐eluting stents group compared with the bare‐metal stents group; and 13 trials were not randomised clinical trials. For further details see <a href="./references#CD012481-sec-0200" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012481-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>Based on the information we collected from the published reports and received from authors, we judged all 25 trials (26 comparisons) to be at high risk of bias. We judged many trials to be at unclear risk of bias in several domains, and we were unable to obtain additional information from the authors when contacted. Additional information is provided in the 'Risk of bias' summary (<a href="#CD012481-fig-0002">Figure 2</a>), 'Risk of bias' graph (<a href="#CD012481-fig-0003">Figure 3</a>), and in the <a href="./references#CD012481-sec-0199" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD012481-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012481-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012481-sec-0063"> <h4 class="title">Allocation</h4> <p>The generation of the allocation sequence was at low risk of bias in 11 trials. The remaining 14 trials were described as being randomised, but the method used for sequence generation was not mentioned. </p> <p>The method used to conceal allocation was at low risk of bias in 12 trials. In the remaining 13 trials the method used for allocation concealment was insufficiently described. </p> </section> <section id="CD012481-sec-0064"> <h4 class="title">Blinding</h4> <p>The blinding of participants was at low risk of bias in one trial (<a href="./references#CD012481-bbs2-0009" title="RemkesWS , BadingsEA , HermanidesRS , RasoulS , DambrinkJHE , KoopmansPC , et al. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. Open Heart2016;3(2):e000455. ">ELISA‐3 2016</a>). Nine trials stated that participants and personnel were not blinded. In the remaining 15 trials the method used to blind participants and personnel was insufficiently described. </p> <p>The blinding of outcome assessors was performed and adequately described in 11 trials. One trial stated that outcome assessors were not blinded. In the remaining 13 trials the method used to blind outcome assessors was insufficiently described. </p> </section> <section id="CD012481-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen trials adequately addressed incomplete outcome data. In the remaining 12 trials the method used to handle incomplete outcome data was insufficiently described. </p> </section> <section id="CD012481-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Four trials reported the results of the outcomes as specified in their respective protocols, or reported our primary outcomes, resulting in a judgement of low risk of bias according to our predefined 'Risk of bias' assessment. Five trials did not report the same outcomes as stated in the pre‐published protocol. For the remaining 16 trials, we could not obtain a protocol and the trial did not report our primary outcomes sufficiently. </p> </section> <section id="CD012481-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>Four trials had no other biases, resulting in a judgement of low risk of bias. Eleven trials were industry funded, resulting in an assessment of high risk of bias. The remaining 10 trials did not report how they were funded and were therefore judged to be at unclear risk of bias. </p> </section> </section> <section id="CD012481-sec-0068"> <h3 class="title" id="CD012481-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD012481-tbl-0001"><b>Summary of findings 1</b> Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</a> </p> <section id="CD012481-sec-0069"> <h4 class="title">Results at maximum follow‐up</h4> <section id="CD012481-sec-0070"> <h5 class="title">Primary outcomes</h5> <section id="CD012481-sec-0071"> <h6 class="title">All‐cause mortality</h6> <p>Twenty‐one out of 25 trials (22 comparisons) with a total of 11,250 participants and a median follow‐up of 12 months (range 1 to 72 months) reported all‐cause mortality at maximum follow‐up. A total of 431/6250 (6.87%) participants receiving drug‐eluting stents died versus 387/5000 (7.74%) participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.78 to 1.03, 11,250 participants, 21 trials/22 comparisons, low‐quality evidence, <a href="./references#CD012481-fig-0007" title="">Analysis 1.1</a>). Hence, the absolute risk for mortality at maximum follow‐up was 6.97% in the drug‐eluting stents group compared with 7.74% in the bare‐metal stents group. </p> <section id="CD012481-sec-0072"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.68) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0073"> <p><b>Trial Sequential Analysis</b></p> <p>Trial Sequential Analysis showed that there was not enough information to confirm or reject that drug‐eluting stents versus bare‐metal stents results in a risk ratio reduction (RRR) of 10% on all‐cause mortality at maximum follow‐up (<a href="#CD012481-fig-0004">Figure 4</a>). The Trial Sequential Analysis‐adjusted CI was 0.70 to 1.14. </p> <div class="figure" id="CD012481-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on all‐cause mortality at maximum follow‐up in 21 trials. The diversity‐adjusted required information size (RIS) was calculated based on mortality in the control group of 7.76%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 45,046 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines). The cumulative Z‐curve did not cross the inner‐wedge futility line (the inner‐wedge futility could not be calculated due to too little information). Additionally, the cumulative Z‐score did not cross the RIS. The green dotted line shows conventional boundaries (2.0%)." data-id="CD012481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on all‐cause mortality at maximum follow‐up in 21 trials. The diversity‐adjusted required information size (RIS) was calculated based on mortality in the control group of 7.76%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 45,046 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines). The cumulative Z‐curve did not cross the inner‐wedge futility line (the inner‐wedge futility could not be calculated due to too little information). Additionally, the cumulative Z‐score did not cross the RIS. The green dotted line shows conventional boundaries (2.0%). </p> </div> </div> </div> </section> <section id="CD012481-sec-0074"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.90). Bayes factor of 0.79 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of a beneficial effect of drug‐eluting stent on all‐cause mortality at maximum follow‐up. </p> </section> <section id="CD012481-sec-0075"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias had the potential to influence the results (best‐worst meta‐analysis (RR 0.60, 95% CI 0.44 to 0.80, 11,775 participants, 21 trials/22 comparisons, <a href="./references#CD012481-fig-0008" title="">Analysis 1.2</a>); worst‐best meta‐analysis (RR 1.27, 95% CI 0.99 to 1.64, 11,775 participants, 21 trials/22 comparisons, <a href="./references#CD012481-fig-0009" title="">Analysis 1.3</a>)). Data were imputed for 11 trials. </p> <p>Visual inspection of the funnel plots showed some signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.19). Using the trim and fill method, we found our meta‐analysis results were not affected. Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0076"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed acute coronary syndrome (ACS) participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD012481-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD012481-fig-0012" title="">Analysis 1.6</a>; <a href="./references#CD012481-fig-0013" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD012481-sec-0077"> <h6 class="title">Serious adverse events</h6> <p>Twenty‐two out of 25 (23 comparisons) trials with a total of 11,724 participants and a median follow‐up of 12 months (range 1 to 72) reported serious adverse events at maximum follow‐up. A total of 1292/6484 (19.92%) participants receiving drug‐eluting stents had a serious adverse event versus 1206/5240 (23.01%) participants receiving bare‐metal stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of serious adverse events at maximum follow‐up (RR 0.80, 95% CI 0.74 to 0.86, 11,724 participants, 22 trials/23 comparisons, low‐quality evidence, <a href="./references#CD012481-fig-0014" title="">Analysis 1.8</a>). Hence, the absolute risk for serious adverse events at maximum follow‐up was 18.04% in the drug‐eluting stents group compared with 23.01% in the bare‐metal stents group. </p> <section id="CD012481-sec-0078"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 22%; P = 0.17) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0079"> <p><b>Trial Sequential Analysis</b></p> <p>Trial Sequential Analysis showed that the Z‐curve crossed the boundary for benefit. Hence, there seems to be firm evidence that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% or more on the risk of a serious adverse event at maximum follow‐up (<a href="#CD012481-fig-0005">Figure 5</a>). In accordance, the Trial Sequential Analysis‐adjusted CI was 0.65 to 0.93. We did not calculate a Trial Sequential Analysis of the CI limit closest to zero effect, as we had already conducted a Trial Sequential Analysis of 10%, which was lower than the limit of the CI (14%). </p> <div class="figure" id="CD012481-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on serious adverse events at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of serious adverse events in the control group of 22.95%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 24,853 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (2.0%)." data-id="CD012481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on serious adverse events at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of serious adverse events in the control group of 22.95%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 24,853 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (2.0%). </p> </div> </div> </div> </section> <section id="CD012481-sec-0080"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.80). Bayes factor of 0.069 was below the Bayes factor threshold for significance of 0.1, supporting that there seems to be evidence of an effect of drug‐eluting stents on serious adverse events at maximum follow‐up. </p> </section> <section id="CD012481-sec-0081"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.67, 95% CI 0.62 to 0.71, 12,249 participants, 22 trials/23 comparisons, <a href="./references#CD012481-fig-0015" title="">Analysis 1.9</a>); worst‐best case meta‐analysis (RR 0.98, 95% CI 0.91 to 1.05, 12,249 participants, 22 trials/23 comparisons, <a href="./references#CD012481-fig-0016" title="">Analysis 1.10</a>)). Data were imputed for 11 trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.08). Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0082"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD012481-fig-0018" title="">Analysis 1.12</a>; <a href="./references#CD012481-fig-0019" title="">Analysis 1.13</a>; <a href="./references#CD012481-fig-0020" title="">Analysis 1.14</a>). </p> </section> </section> <section id="CD012481-sec-0083"> <h6 class="title">Major cardiovascular events</h6> <p>Nineteen out of 25 trials (20 comparisons) with a total of 10,939 participants and a median follow‐up of 12 months (range 1 to 72) reported major cardiovascular events (defined as cardiovascular death or myocardial infarction) at maximum follow‐up. A total of 400/6096 (6.56%) participants receiving drug‐eluting stents had a major cardiovascular event versus 321/4843 (6.63%) participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.96, 95% CI 0.83 to 1.11, 10,939 participants, 19 trials/20 comparisons, very low‐quality evidence, <a href="./references#CD012481-fig-0021" title="">Analysis 1.15</a>). Hence, the absolute risk for major cardiovascular event at maximum follow‐up was 6.36% in the drug‐eluting stents group compared with 6.63% in the bare‐metal stents group. </p> <section id="CD012481-sec-0084"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.87) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0085"> <p><b>Trial Sequential Analysis</b></p> <p>Trial Sequential Analysis showed that there was not enough information to confirm or reject that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% on major cardiovascular events at maximum follow‐up. The Trial Sequential Analysis‐adjusted CI was 0.53 to 1.76. </p> </section> <section id="CD012481-sec-0086"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.96). Bayes factor of 0.57 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on major cardiovascular events at maximum follow‐up. </p> </section> <section id="CD012481-sec-0087"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.53, 95% CI 0.39 to 0.72, 11,596 participants, 19 trials/20 comparisons, <a href="./references#CD012481-fig-0022" title="">Analysis 1.16</a>); worst‐best case meta‐analysis (RR 1.40, 95% CI 0.97 to 2.00, 11,596 participants, 19 trials/20 comparisons, <a href="./references#CD012481-fig-0023" title="">Analysis 1.17</a>)). Data were imputed for nine trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.21). Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0088"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0024" title="">Analysis 1.18</a>; <a href="./references#CD012481-fig-0025" title="">Analysis 1.19</a>; <a href="./references#CD012481-fig-0026" title="">Analysis 1.20</a>; <a href="./references#CD012481-fig-0027" title="">Analysis 1.21</a>). </p> </section> </section> </section> <section id="CD012481-sec-0089"> <h5 class="title">Quality of life</h5> <p>No trials reported quality of life at any time point.</p> </section> </section> <section id="CD012481-sec-0090"> <h4 class="title">Secondary outcomes</h4> <section id="CD012481-sec-0091"> <h5 class="title">Cardiovascular mortality</h5> <p>Fourteen out of 25 trials (15 comparisons) with a total of 9248 participants and a mean follow‐up of 44.5 months (range 3 to 137) reported cardiovascular mortality at maximum follow‐up. A total of 260/5402 (4.81%) participants receiving drug‐eluting stents died by a cardiovascular cause versus 223/3846 (5.80%) participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.91, 95% CI 0.76 to 1.09, 9248 participants, 14 trials/15 comparisons, very low‐quality evidence, <a href="./references#CD012481-fig-0028" title="">Analysis 1.22</a>). </p> <section id="CD012481-sec-0092"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.44) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0093"> <h6 class="title">Trial Sequential Analysis</h6> <p>Trial Sequential Analysis showed that there was not enough information to confirm or reject that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% on cardiovascular mortality at maximum follow‐up. The Trial Sequential Analysis‐adjusted CI was 0.44 to 1.89. </p> </section> <section id="CD012481-sec-0094"> <h6 class="title">Bayes factor</h6> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.91). Bayes factor of 0.9 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on cardiovascular mortality at maximum follow‐up. </p> </section> <section id="CD012481-sec-0095"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.50, 95% CI 0.32 to 0.77, 9742 participants, 14 trials, <a href="./references#CD012481-fig-0029" title="">Analysis 1.23</a>); worst‐best case meta‐analysis (RR 1.49, 95% CI 1.06 to 2.11, 9742 participants, 14 trials, <a href="./references#CD012481-fig-0030" title="">Analysis 1.24</a>)). Data were imputed for eight trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.39). Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0096"> <h6 class="title">Subgroup analyses</h6> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0031" title="">Analysis 1.25</a>; <a href="./references#CD012481-fig-0032" title="">Analysis 1.26</a>; <a href="./references#CD012481-fig-0033" title="">Analysis 1.27</a>; <a href="./references#CD012481-fig-0034" title="">Analysis 1.28</a>). </p> </section> </section> <section id="CD012481-sec-0097"> <h5 class="title">Myocardial infarction</h5> <p>Eighteen out of 25 trials (19 comparisons) with a total of 10,217 participants and a mean follow‐up of 44.5 months (range 3 to 137) reported myocardial infarction at maximum follow‐up. A total of 296/5732 (5.15%) participants receiving drug‐eluting stents had a myocardial infarction versus 214/4485 (4.75%) participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.98, 95% CI 0.82 to 1.18, 10,217 participants, 18 trials/19 comparisons, very low‐quality evidence, <a href="./references#CD012481-fig-0035" title="">Analysis 1.29</a>). </p> <section id="CD012481-sec-0098"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.56) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0099"> <h6 class="title">Trial Sequential Analysis</h6> <p>Trial Sequential Analysis showed that there was not enough information to confirm or reject that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% on myocardial infarction at maximum follow‐up. The Trial Sequential Analysis‐adjusted CI was 0.46 to 2.08. </p> </section> <section id="CD012481-sec-0100"> <h6 class="title">Bayes factor</h6> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.98). Bayes factor of 1.09 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on myocardial infarction at maximum follow‐up. </p> </section> <section id="CD012481-sec-0101"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.46, 95% CI 0.33 to 0.66, 10,851 participants, 18 trials/19 comparisons, <a href="./references#CD012481-fig-0036" title="">Analysis 1.30</a>); worst‐best case meta‐analysis (RR 1.56, 95% CI 1.00 to 2.45, 10,851 participants, 18 trials/19 comparisons, <a href="./references#CD012481-fig-0037" title="">Analysis 1.31</a>)). Data were imputed for 10 trials. </p> <p>Visual inspection of the funnel plots showed no signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.39). Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0102"> <h6 class="title">Subgroup analyses</h6> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0038" title="">Analysis 1.32</a>; <a href="./references#CD012481-fig-0039" title="">Analysis 1.33</a>; <a href="./references#CD012481-fig-0040" title="">Analysis 1.34</a>; <a href="./references#CD012481-fig-0041" title="">Analysis 1.35</a>). </p> </section> </section> <section id="CD012481-sec-0103"> <h5 class="title">Angina</h5> <p>No trials reported angina at any time point.</p> </section> <section id="CD012481-sec-0104"> <h5 class="title">Exploratory outcomes</h5> <section id="CD012481-sec-0105"> <h6 class="title">Stent thrombosis</h6> <p>Twenty out of 25 trials (21 comparisons) with a total of 11,350 participants and a mean follow‐up of 44.5 months (range 3 to 137) reported stent thrombosis at maximum follow‐up. A total of 268/6299 (4.23%) participants receiving drug‐eluting stents had a stent thrombosis versus 223/5051 (4.41%) of participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.96, 95% CI 0.80 to 1.16, 11,350 participants, 20 trials/21 comparisons, <a href="./references#CD012481-fig-0042" title="">Analysis 1.36</a>). </p> <section id="CD012481-sec-0106"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.53) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0107"> <p><b>Trial Sequential Analysis</b></p> <p>Trial Sequential Analysis showed that there was not enough information to confirm or reject that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% on stent thrombosis at maximum follow‐up. The Trial Sequential Analysis‐adjusted CI was 0.45 to 2.05. </p> </section> <section id="CD012481-sec-0108"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.96). Bayes factor of 1.03 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on stent thrombosis at maximum follow‐up. </p> </section> <section id="CD012481-sec-0109"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.47, 95% CI 0.32 to 0.67, 12,007 participants, 20 trials/21 comparisons, <a href="./references#CD012481-fig-0043" title="">Analysis 1.37</a>); worst‐best case meta‐analysis (RR 1.55, 95% CI 1.12 to 2.15, 12,007 participants, 20 trials/21 comparisons, <a href="./references#CD012481-fig-0044" title="">Analysis 1.38</a>)). Data were imputed for 12 trials. </p> <p>Visual inspection of the funnel plots showed signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.05). The trim and fill method did not change our results. Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0110"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0045" title="">Analysis 1.39</a>; <a href="./references#CD012481-fig-0046" title="">Analysis 1.40</a>; <a href="./references#CD012481-fig-0047" title="">Analysis 1.41</a>; <a href="./references#CD012481-fig-0048" title="">Analysis 1.42</a>). </p> </section> </section> <section id="CD012481-sec-0111"> <h6 class="title">Target vessel revascularisation</h6> <p>Twenty‐two out of 25 trials (23 comparisons) with a total of 11,770 participants and a median follow‐up of 12 months (range 1 to 72) reported target vessel revascularisation at maximum follow‐up. A total of 576/6504 (8.85%) participants receiving drug‐eluting stents had a target vessel revascularisation versus 702/5266 (13.33%) participants receiving bare‐metal stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of target vessel revascularisation at maximum follow‐up (RR 0.58, 95% CI 0.52 to 0.65, 11,770 participants, 22 trials/23 comparisons, <a href="./references#CD012481-fig-0049" title="">Analysis 1.43</a>). </p> <section id="CD012481-sec-0112"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots indicated no statistical heterogeneity. The test for statistical heterogeneity (I<sup>2</sup> = 37%; P = 0.04) indicated moderate heterogeneity. </p> </section> <section id="CD012481-sec-0113"> <p><b>Trial Sequential Analysis</b></p> <p>Trial Sequential Analysis showed that the Z‐curve crossed the boundary for benefit. Hence, there seems to be firm evidence that drug‐eluting stents versus bare‐metal stents results in a RRR of 30% or more on the risk of target vessel revascularisation at maximum follow‐up (<a href="#CD012481-fig-0006">Figure 6</a>). In accordance, the Trial Sequential Analysis‐adjusted CI was 0.50 to 0.67. </p> <div class="figure" id="CD012481-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on target vessel revascularisation at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of target vessel revascularisations in the control group of 13.28%; risk ratio reduction (RRR) of 30% in the experimental group; type I error of 3.33%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 5361 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (3.33%)." data-id="CD012481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on target vessel revascularisation at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of target vessel revascularisations in the control group of 13.28%; risk ratio reduction (RRR) of 30% in the experimental group; type I error of 3.33%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 5361 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (3.33%). </p> </div> </div> </div> </section> <section id="CD012481-sec-0114"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.70 and the meta‐analysis result (RR 0.58). Bayes factor of 0.0002 was below the Bayes factor threshold for significance of 0.1, supporting that there seems to be evidence of an effect of drug‐eluting stents on target vessel revascularisation at maximum follow‐up. </p> </section> <section id="CD012481-sec-0115"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case random‐effects meta‐analysis (RR 0.41, 95% CI 0.37 to 0.45, 12,368 participants, 22 trials/23 comparisons, <a href="./references#CD012481-fig-0050" title="">Analysis 1.44</a>); worst‐best case meta‐analysis (RR 0.98, 95% CI 0.89 to 1.07, 12,368 participants, 22 trials/23 comparisons, <a href="./references#CD012481-fig-0051" title="">Analysis 1.45</a>)). Data were imputed for 14 trials. </p> <p>Visual inspection of the funnel plots showed no clear signs of asymmetry. Harbord's test for small‐study effects was not significant (P = 0.05). Hence, we assessed the risk of publication bias as low. </p> </section> <section id="CD012481-sec-0116"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0052" title="">Analysis 1.46</a>; <a href="./references#CD012481-fig-0053" title="">Analysis 1.47</a>; <a href="./references#CD012481-fig-0054" title="">Analysis 1.48</a>; <a href="./references#CD012481-fig-0055" title="">Analysis 1.49</a>). </p> </section> </section> </section> </section> <section id="CD012481-sec-0117"> <h4 class="title">Results at one‐month follow‐up</h4> <section id="CD012481-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD012481-sec-0119"> <h6 class="title">All‐cause mortality</h6> <p>Six out of 25 trials with a total of 3233 participants reported target vessel revascularisation at one‐month follow‐up. A total of 25/1621 (1.54%) participants receiving drug‐eluting stents had a target vessel revascularisation versus 51/1612 (3.16%) participants receiving bare‐metal stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of target vessel revascularisation at one‐month follow‐up (RR 0.50, 95% CI 0.31 to 0.82, 3233 participants, 6 trials, <a href="./references#CD012481-fig-0056" title="">Analysis 2.1</a>). </p> <section id="CD012481-sec-0120"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.55) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0121"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.70 and the meta‐analysis result (RR 0.50). Bayes factor of 0.26 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on target vessel revascularisation at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0122"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst case meta‐analysis (RR 0.41, 95% CI 0.26 to 0.66, 3251 participants, 6 trials, <a href="./references#CD012481-fig-0057" title="">Analysis 2.2</a>); worst‐best case meta‐analysis (RR 0.62, 95% CI 0.40 to 0.98, 3251 participants, 6 trials, <a href="./references#CD012481-fig-0058" title="">Analysis 2.3</a>)). Data were imputed for two trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0123"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0059" title="">Analysis 2.4</a>; <a href="./references#CD012481-fig-0060" title="">Analysis 2.5</a>; <a href="./references#CD012481-fig-0061" title="">Analysis 2.6</a>). </p> </section> </section> <section id="CD012481-sec-0124"> <h6 class="title">Serious adverse events</h6> <p>Seven out of 25 trials with a total of 3313 participants reported serious adverse events at one‐month follow‐up. A total of 48/1661 (2.89%) participants receiving drug‐eluting stents had a serious adverse event versus 74/1652 (4.48%) participants receiving bare‐metal‐stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of serious adverse events at one‐month follow‐up (RR 0.65, 95% CI 0.45 to 0.93, 3313 participants, 7 trials, <a href="./references#CD012481-fig-0062" title="">Analysis 2.7</a>). </p> <section id="CD012481-sec-0125"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.94) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0126"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR of 0.90 and the meta‐analysis result (RR 0.65). Bayes factor of 0.68 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no beneficial significant effect of drug‐eluting stents on serious adverse events at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0127"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.56, 95% CI 0.40 to 0.80, 3331 participants, 7 trials, <a href="./references#CD012481-fig-0063" title="">Analysis 2.8</a>); worst‐best case meta‐analysis (RR 0.73, 95% CI 0.52 to 1.03, 3331 participants, 7 trials, <a href="./references#CD012481-fig-0064" title="">Analysis 2.9</a>)). Data were imputed for three trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0128"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0065" title="">Analysis 2.10</a>; <a href="./references#CD012481-fig-0066" title="">Analysis 2.11</a>; <a href="./references#CD012481-fig-0067" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD012481-sec-0129"> <h6 class="title">Major cardiovascular events</h6> <p>Six out of 25 trials with a total of 3150 participants reported major cardiovascular events (defined as cardiovascular mortality or myocardial infarction) at one‐month follow‐up. A total of 30/1580 (1.90%) participants receiving drug‐eluting stents had a major cardiovascular event versus 44/1570 (2.80%) participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.68, 95% CI 0.43 to 1.08, 3150 participants, 6 trials, <a href="./references#CD012481-fig-0068" title="">Analysis 2.13</a>). </p> <section id="CD012481-sec-0130"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.98) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0131"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.90 and the meta‐analysis result (RR 0.68). Bayes factor of 0.93 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on major cardiovascular events at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0132"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.54, 95% CI 0.35 to 0.84, 3168 participants, 6 trials, <a href="./references#CD012481-fig-0069" title="">Analysis 2.14</a>); worst‐best case meta‐analysis (RR 0.82, 95% CI 0.53 to 1.27, 3168 participants, 6 trials <a href="./references#CD012481-fig-0070" title="">Analysis 2.15</a>)). Data were imputed for three trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0133"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0071" title="">Analysis 2.16</a>; <a href="./references#CD012481-fig-0072" title="">Analysis 2.17</a>; <a href="./references#CD012481-fig-0073" title="">Analysis 2.18</a>). </p> </section> </section> </section> <section id="CD012481-sec-0134"> <h5 class="title">Secondary outcomes</h5> <section id="CD012481-sec-0135"> <h6 class="title">Cardiovascular mortality</h6> <p>Five out of 25 trials with a total of 2406 participants reported cardiovascular mortality at one‐month follow‐up. A total of 22/1208 (1.82%) participants receiving drug‐eluting stents died by a cardiovascular cause versus 30/1198 (2.50%) of participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.73, 95% CI 0.43 to 1.25, 2406 participants, 5 trials, <a href="./references#CD012481-fig-0074" title="">Analysis 2.19</a>). </p> <section id="CD012481-sec-0136"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the test for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.88) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0137"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.90 and the meta‐analysis result (RR 0.73). Bayes factor of 1.02 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on cardiovascular mortality at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0138"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.53, 95% CI 0.32 to 0.88, 2423 participants, 5 trials, <a href="./references#CD012481-fig-0075" title="">Analysis 2.20</a>); worst‐best case meta‐analysis (RR 0.90, 95% CI 0.54 to 1.50, 2423 participants, 5 trials, ; <a href="./references#CD012481-fig-0076" title="">Analysis 2.21</a>)). Data were imputed for two trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0139"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0077" title="">Analysis 2.22</a>; <a href="./references#CD012481-fig-0078" title="">Analysis 2.23</a>; <a href="./references#CD012481-fig-0079" title="">Analysis 2.24</a>). </p> </section> </section> <section id="CD012481-sec-0140"> <h6 class="title">Myocardial infarction</h6> <p>Six out of 25 trials with a total of 3150 participants reported myocardial infarction at one‐month follow‐up. A total of 13/1580 (0.82%) participants receiving drug‐eluting stents had a myocardial infarction versus 26/1570 (1.66%) of participants receiving bare‐metal stents. Meta‐analysis showed no evidence of a difference (RR 0.51, 95% CI 0.26 to 0.98, 3150 participants, 6 trials, <a href="./references#CD012481-fig-0080" title="">Analysis 2.25</a>). </p> <section id="CD012481-sec-0141"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.99) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0142"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.90 and the meta‐analysis result (RR 0.51). Bayes factor of 0.88 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on myocardial infarction at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0143"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.37, 95% CI 0.20 to 0.68, 3168 participants, 6 trials, <a href="./references#CD012481-fig-0081" title="">Analysis 2.26</a>); worst‐best case meta‐analysis: (RR 0.74, 95% CI 0.41 to 1.32, 3168 participants, 6 trials, <a href="./references#CD012481-fig-0082" title="">Analysis 2.27</a>)). Data were imputed for three trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0144"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0083" title="">Analysis 2.28</a>; <a href="./references#CD012481-fig-0084" title="">Analysis 2.29</a>; <a href="./references#CD012481-fig-0085" title="">Analysis 2.30</a>). </p> </section> </section> </section> <section id="CD012481-sec-0145"> <h5 class="title">Exploratory outcomes</h5> <section id="CD012481-sec-0146"> <h6 class="title">Stent thrombosis</h6> <p>Five out of 25 trials with a total of 3070 participants reported stent thrombosis at one‐month follow‐up. A total of 15/1540 (0.97%) participants receiving drug‐eluting stents had a stent thrombosis versus 31/1530 (2.03%) participants receiving bare‐metal stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of stent thrombosis (RR 0.48, 95% CI 0.26 to 0.90, 3070 participants, 5 trials, <a href="./references#CD012481-fig-0086" title="">Analysis 2.31</a>). </p> <section id="CD012481-sec-0147"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.88) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0148"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.90 and the meta‐analysis result (RR 0.48). Bayes factor of 0.87 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on stent thrombosis at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0149"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the results (best‐worst case meta‐analysis (RR 0.36, 95% CI 0.20 to 0.65, 3088 participants, 5 trials, <a href="./references#CD012481-fig-0087" title="">Analysis 2.32</a>); worst‐best case meta‐analysis (RR 0.68, 95% CI 0.39 to 1.18, 3088 participants, 5 trials, <a href="./references#CD012481-fig-0088" title="">Analysis 2.33</a>)). Data were imputed for three trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0150"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), length of maximum follow‐up, and protocol registration status (<a href="./references#CD012481-fig-0089" title="">Analysis 2.34</a>; <a href="./references#CD012481-fig-0090" title="">Analysis 2.35</a>; <a href="./references#CD012481-fig-0091" title="">Analysis 2.36</a>). </p> </section> </section> <section id="CD012481-sec-0151"> <h6 class="title">Target vessel revascularisation</h6> <p>Six out of 25 trials with a total of 3233 participants reported target vessel revascularisation at one‐month follow‐up. A total of 25/1621 (1.54%) participants receiving drug‐eluting stents had a target vessel revascularisation versus 51/1612 (3.16%) participants receiving bare‐metal stents. Meta‐analysis showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of target vessel revascularisation at one‐month follow‐up (RR 0.50, 95% CI 0.31 to 0.82, 3233 participants, 6 trials, <a href="./references#CD012481-fig-0092" title="">Analysis 2.37</a>). </p> <section id="CD012481-sec-0152"> <p><b>Heterogeneity</b></p> <p>Visual inspection of the forest plots and the tests for statistical heterogeneity (I<sup>2</sup> = 0%; P = 0.55) indicated that heterogeneity might not be important. </p> </section> <section id="CD012481-sec-0153"> <p><b>Bayes factor</b></p> <p>Bayes factor was calculated based on a RR 0.70 and the meta‐analysis result (RR 0.50). Bayes factor of 0.26 was above the Bayes factor threshold for significance of 0.1, supporting that there seems to be no evidence of an effect of drug‐eluting stents on target vessel revascularisation at one‐month follow‐up. </p> </section> <section id="CD012481-sec-0154"> <p><b>Risk of bias and sensitivity analyses</b></p> <p>We assessed the risk of bias of the outcome result in all trials as high, therefore we could not conduct sensitivity analysis for bias. </p> <p>The best‐worst case and worst‐best case meta‐analyses showed that incomplete outcome data bias alone did not have the potential to influence the results (best‐worst case meta‐analysis (RR 0.41, 95% CI 0.26 to 0.66, 3251 participants, 6 trials, <a href="./references#CD012481-fig-0093" title="">Analysis 2.38</a>); worst‐best case meta‐analysis (RR 0.62, 95% CI 0.40 to 0.98, 3251 participants, 6 trials, <a href="./references#CD012481-fig-0094" title="">Analysis 2.39</a>)). Data were imputed for two trials. </p> <p>We did not visually inspect the funnel plots or perform Harbord's test as fewer than 10 trials were included for this outcome. Hence, we assessed the risk of publication bias as unclear. </p> </section> <section id="CD012481-sec-0155"> <p><b>Subgroup analyses</b></p> <p>The formal test for subgroup difference in Review Manager 5 found no evidence of a difference in subgroup analyses according to type of drug‐eluting stent, type of participants (STEMI compared with mixed ACS participants), and protocol registration status (<a href="./references#CD012481-fig-0095" title="">Analysis 2.40</a>; <a href="./references#CD012481-fig-0096" title="">Analysis 2.41</a>; <a href="./references#CD012481-fig-0097" title="">Analysis 2.42</a>). </p> </section> </section> </section> <section id="CD012481-sec-0156"> <h5 class="title">GRADE assessments</h5> <p>Our main results are summarised in the <a href="./full#CD012481-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012481-sec-0157" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012481-sec-0157"></div> <section id="CD012481-sec-0158"> <h3 class="title" id="CD012481-sec-0158">Summary of main results</h3> <p>We included 25 trials (26 comparisons) randomising a total of 12,503 participants. All trials and outcomes were at high risk of bias, and the quality of the evidence according to the GRADE assessment was low to very low for all outcomes. </p> <p>Meta‐analyses showed no evidence of a difference when comparing drug‐eluting stents with bare‐metal stents on the risk of all‐cause mortality and on major cardiovascular events. The results of our Trial Sequential Analysis showed that we did not have sufficient information to confirm or reject our anticipated RRR of 10% on both risk of all‐cause mortality and on major cardiovascular events. </p> <p>Meta‐analyses showed evidence of a beneficial effect of drug‐eluting stents compared with bare‐metal stents on the risk of serious adverse events. The Trial Sequential Analysis for serious adverse events showed that the Z‐curve crossed the boundary for benefit for drug‐eluting stents. Hence, there seems to be firm evidence that drug‐eluting stents versus bare‐metal stents results in a RRR of 10% or more on the risk of a serious adverse event at maximum follow‐up. When assessing specific types of events included in the serious adverse event outcome separately, we found the majority of the events were target vessel revascularisation. </p> <p>Formal tests for subgroup differences showed no evidence of a difference according to drug‐eluting stent type (including bioresorbable stents), type of participants (STEMI, NSTEMI, ACS), protocol registration status, and length of follow‐up for any of our primary outcomes. </p> <p>Meta‐analyses showed no evidence of a difference when comparing drug‐eluting stents with bare‐metal stents on the risk of cardiovascular mortality and myocardial infarction. The results of our Trial Sequential Analysis showed that we did not have sufficient information to confirm or reject our anticipated RRR of 10% on both risk of cardiovascular mortality and on myocardial infarction. </p> <p>No trials reported results on angina or quality of life.</p> </section> <section id="CD012481-sec-0159"> <h3 class="title" id="CD012481-sec-0159">Overall completeness and applicability of evidence</h3> <p>This review provides the most comprehensive and contemporary appraisal of the evidence on drug‐eluting stents versus bare‐metal stents to date. We searched for published and unpublished trials irrespective of publication type, publication status, publication date, and language. We also searched bibliographies of both Cochrane and non‐Cochrane reviews for any trials we might have missed. The high risk of bias in our trials suggests that our results may show an overestimation of the benefit of drug‐eluting stents and an underestimation of the harm of drug‐eluting stents. </p> <p>No trials reported quality of life or the number of participants with angina.</p> <p>A number of trials did not report data separately on ACS participants and participants with other ischaemic heart disease, therefore we could not include these participants in our analyses. We have included these trials as 'studies awaiting classification'. The results from these trials deviate from our analyses in showing a difference between interventions for major cardiovascular events and myocardial infarction. We have attempted to contact the trial authors for specific information on ACS participants, and hope to receive these data in the future. </p> </section> <section id="CD012481-sec-0160"> <h3 class="title" id="CD012481-sec-0160">Quality of the evidence</h3> <section id="CD012481-sec-0161"> <h4 class="title">Heterogeneity</h4> <p>We assessed the statistical heterogeneity in the planned analyses of our primary and secondary outcomes as low. </p> </section> <section id="CD012481-sec-0162"> <h4 class="title">Risk of systematic error ('bias')</h4> <p>Our 'Risk of bias' assessment showed that all trials were at high risk of bias. It is, therefore, highly probable that our review results are also biased, that is that there is a great risk that our results overestimate benefits and underestimate harm (<a href="./references#CD012481-bbs2-0117" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ (Clinical Research Ed)2012;344:e1119.">Hrobjartsson 2012</a>; <a href="./references#CD012481-bbs2-0118" title="HrobjartssonA , ThomsenASS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ: Canadian Medical Association Journal2013;185(4):E201-11.">Hrobjartsson 2013</a>; <a href="./references#CD012481-bbs2-0119" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , RasmussenJV , HildenJ , et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. International Journal of Epidemiology2014;43(3):937-48.">Hrobjartsson 2014</a>; <a href="./references#CD012481-bbs2-0120" title="HrobjartssonA , EmanuelssonF , Skou ThomsenAS , HildenJ , BrorsonS . Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. International Journal of Epidemiology2014;43(4):1272-83.">Hrobjartsson 2014a</a>; <a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>; <a href="./references#CD012481-bbs2-0136" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012481-bbs2-0162" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012</a>; <a href="./references#CD012481-bbs2-0165" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD012481-bbs2-0198" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We have downgraded all of our outcomes by two levels for a very serious risk of bias. </p> <p>Only one trial had low risk of bias in blinding of participants and personnel, due to the nature of the PCI procedure. Trials without blinding of participants and personnel tend to overestimate benefits and underestimate harm (<a href="./references#CD012481-bbs2-0119" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , RasmussenJV , HildenJ , et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. International Journal of Epidemiology2014;43(3):937-48.">Hrobjartsson 2014</a>; <a href="./references#CD012481-bbs2-0150" title="PocockSJ , ClaytonTC , StoneGW . Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology2015;66(24):2757-66.">Pocock 2015</a>; <a href="./references#CD012481-bbs2-0162" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012</a>; <a href="./references#CD012481-bbs2-0198" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). This may be due to a lack of expectations in a control group; differential behaviours across intervention groups (e.g. differential dropout or differential cross‐over to an alternative intervention); or different perception and reporting of an outcome such as pain or feeling more obliged to consider participants for target vessel revascularisation when knowing that a participant had received a bare‐metal stent (<a href="./references#CD012481-bbs2-0114" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random-effects meta-analysis. Statistics in Medicine2011;30(9):903-21. [PMID: 21472757]">Higgins 2011a</a>. </p> <p>We assessed 12 out of 25 trials as at unclear or high risk of bias for the incomplete outcome data bias domain. Our best‐worst case and worst‐best case analyses showed that incomplete outcome data alone had the potential to change our results at maximum follow‐up. Where insufficient data were reported by the trialists, we attempted to contact the authors, but frequently did not receive a reply. Hence, the extent of the incomplete outcome data was often unclear. Our best‐worst case and worst‐best case analyses might underestimate the potential impact of missing data because only the data on the reported population were used if no other information was available. Incomplete outcome data bias might potentially have an even greater bias impact than our best‐worst case/worst‐best case scenarios show, that is the ’true’ difference between the actually observed cases and the intention‐to‐treat population might be larger than our data suggest. </p> </section> <section id="CD012481-sec-0163"> <h4 class="title">Publication bias</h4> <p>Most of our funnel plots and Harbord's tests did not show clear signs of asymmetry (only all‐cause mortality and stent thrombosis showed some signs). We assessed those that did show signs with a trim and fill method, which showed that the results were not changed. Hence, there was no strong suspicion of significant small‐study bias or publication bias for any of our results. </p> </section> <section id="CD012481-sec-0164"> <h4 class="title">Indirectness</h4> <p>In our review the composite outcome 'serious adverse events' was largely driven by target vessel revascularisation. The reason for performing target vessel revascularisation is typically based on clinical characteristics such as unstable angina or an angiographic indication. The angiographic indication could be problematic: it may be that there is an angiographic difference at follow‐up between participants receiving drug‐eluting stents and participants receiving bare‐metal stents, but that this angiographic difference does not necessarily translate into different clinical outcomes. Despite the above, we have not chosen to downgrade for indirectness, but the reader should be aware of this limitation. </p> </section> <section id="CD012481-sec-0165"> <h4 class="title">Imprecision (risk of random error)</h4> <p>The Trial Sequential Analysis of serious adverse events confirmed that we had enough information to assess a 10% RRR at maximum follow‐up. Trial Sequential Analysis of all‐cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction showed that we did not have enough information to assess a 10% RRR at maximum follow‐up, resulting in a GRADE downgrade for imprecision for these outcomes. </p> </section> <section id="CD012481-sec-0166"> <h4 class="title">GRADE</h4> <p>We have assessed the quality of the evidence for the results of each outcome using GRADE (<a href="./full#CD012481-tbl-0001">summary of findings Table 1</a>). The GRADE assessment generally showed the evidence to be of low to very low quality. Reasons for the GRADE assessment are given in the footnotes of the <a href="./full#CD012481-tbl-0001">summary of findings Table 1</a>. </p> </section> </section> <section id="CD012481-sec-0167"> <h3 class="title" id="CD012481-sec-0167">Potential biases in the review process</h3> <section id="CD012481-sec-0168"> <h4 class="title">Strengths</h4> <p>Our review has several strengths. We included trials regardless of language of publication and whether they reported data for the outcomes we had planned to assess. Where additional information was needed, we contacted all relevant authors. We included more participants than any previous systematic review, which gave us increased power and precision to detect any significant differences between the intervention and the control group. We followed our peer‐reviewed protocol, which was published before the literature search began (<a href="./references#CD012481-bbs2-0201" title="FeinbergJ , NielsenEE , GreenhalghJ , HounsomeJ , SethiNJ , SafiS , et al. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD012481. [DOI: 10.1002/14651858.CD012481]">Feinberg 2016</a>), and we conducted the review using the methods recommended by Cochrane and findings from additional methodological studies (<a href="./references#CD012481-bbs2-0114" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random-effects meta-analysis. Statistics in Medicine2011;30(9):903-21. [PMID: 21472757]">Higgins 2011a</a>). We also performed Trial Sequential Analyses and used an eight‐step procedure to assess if the thresholds for statistical and clinical significance were crossed (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>), which adds further robustness to our results and conclusions. We also tested the robustness of our results with sensitivity analyses (best‐worst case and worst‐best case). Our meta‐analyses had little statistical heterogeneity, strengthening the validity of our results. </p> </section> <section id="CD012481-sec-0169"> <h4 class="title">Limitations</h4> <p>Our systematic review has several limitations. Our findings, interpretations, and conclusions are affected by the quality and quantity of the included trials. The relatively short follow‐up might also make it harder to detect a difference; it may be that longer follow‐up would reveal such a difference. </p> <p>Furthermore, by only including randomised clinical trials and ignoring harms assessed in quasi‐randomised studies and observational studies, we run the risk of focusing overly on potential benefits at the cost of overlooking late and rare harms. </p> <p>Another, and likely often ignored, limitation is the fact that we have compared drug‐eluting stents versus bare‐metal stents without having solid proof that the latter intervention is significantly more beneficial from a statistical and clinical point of view than just balloon dilatation or no intervention at all (see <a href="#CD012481-sec-0012">Description of the intervention</a>). Evidence points in this direction, but solid evidence based on systematic reviews with meta‐analysis and Trial Sequential Analysis taking risks of bias into consideration is lacking (<a href="./references#CD012481-bbs2-0098" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). </p> <p>In our primary analyses, we included only one trial using a biodegradable drug‐eluting stent in the experimental group (<a href="./references#CD012481-bbs2-0001" title="MagroM , RaberL , HegD , TaniwakiM , KelbaekH , OstojicM , et al. The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: a substudy of the COMFORTABLE AMI trial. International Journal of Cardiology2014;175(2):314-22. RaberL , KelbaekH , BaumbachA , TullerD , OstojicM , JuniP , et al. Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 year results of the randomized COMFORTABLE AMI trial. European Heart Journal2016;37:35. RaberL , KelbaekH , OstoijcM , BaumbachA , TullerD , vonBirgelenC , et al. Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design. EuroIntervention2012;7(12):1435-43. [PMID: 22301368]RaberL , KelbaekH , TaniwakiM , OstojicM , HegD , BaumbachA , et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circulation: Cardiovascular Interventions2014;7(3):355-64. RaberL , OstojimM . Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA2012;308(8):777-87. ">COMFORTABLE 2012</a>). Our subgroup assessing different types of drug‐eluting stents compared with bare‐metal stents found no differences between the experimental stents, but this may be due to a low number of included trials evaluating these types of stents. In the future, network meta‐analyses and individual participant data meta‐analysis may assess these types of stents (<a href="./references#CD012481-bbs2-0098" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>; <a href="./references#CD012481-bbs2-0172" title="SkoogM , SaarimäkiJM , GluudC , SheininM , ErlendssonK , AamdalS , et al. Transparency and registration in clinical research in the Nordic countries. The Nordic Trial Alliance Working Group on Transparency and Registration under NordForsk2015.">Skoog 2015</a>)<i>.</i> </p> <p>We used observed data in the estimation of a required information size, which might lead to lack of consistency in stopping boundaries across analyses. The alternative would be to predefine diversity for each analysis the incidence in all of the control groups before data were known. This also has several limitations, that is how these were values estimated, and if they are erroneous then this will lead to erroneous results. We chose from a pragmatic perspective the observed data (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> <section id="CD012481-sec-0170"> <h5 class="title">Composite outcome</h5> <p>To increase the statistical power, we chose to use two composite outcomes: major cardiovascular events and serious adverse events. A potential limitation when using composite outcomes is that each component of a composite outcome will not necessarily have similar degrees of severity, especially with serious adverse events, and this might bias the results of the outcome (<a href="./references#CD012481-bbs2-0098" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). For example, if certain more severe serious adverse events occur in one intervention group and other less severe serious adverse events occur in the other intervention group, then there is a risk of overlooking actual severity differences between the compared groups on this composite outcome (<a href="./references#CD012481-bbs2-0098" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). </p> <p>In our review, the composite outcome serious adverse events was largely driven by target vessel revascularisation. The reason for performing target vessel revascularisation is typically based on clinical characteristics such as unstable angina or an angiographic indication. The angiographic indication could be problematic: it may be that there is an angiographic difference at follow‐up between participants receiving drug‐eluting stents and participants receiving bare‐metal stents, but that this angiographic difference does not necessarily translate into different clinical outcomes. For this reason we did not use the traditional outcome MACE (major adverse cardiac events). MACE usually consists of a composite of cardiac death, myocardial infarction, and either target vessel revascularisation or target lesion revascularisation, but may include other outcomes (<a href="./references#CD012481-bbs2-0128" title="KipKE , HollabaughK , MarroquinOC , WilliamsDO . The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology2008;51(7):701-7. [PMID: 18279733]">Kip 2008</a>). In recent years, two major reports have described and analysed several issues regarding the cardiac composite outcome MACE (<a href="./references#CD012481-bbs2-0085" title="CutlipDE , WindeckerS , MehranR , BoamA , CohenDJ , vanEsGA , et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation2007;115(17):2344-51. [PMID: 17470709]">Cutlip 2007</a>; <a href="./references#CD012481-bbs2-0128" title="KipKE , HollabaughK , MarroquinOC , WilliamsDO . The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology2008;51(7):701-7. [PMID: 18279733]">Kip 2008</a>). The main issues regarding MACE concern the variability and lack of consistency in which outcomes are included in the composite outcome (<a href="./references#CD012481-bbs2-0085" title="CutlipDE , WindeckerS , MehranR , BoamA , CohenDJ , vanEsGA , et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation2007;115(17):2344-51. [PMID: 17470709]">Cutlip 2007</a>; <a href="./references#CD012481-bbs2-0128" title="KipKE , HollabaughK , MarroquinOC , WilliamsDO . The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology2008;51(7):701-7. [PMID: 18279733]">Kip 2008</a>), which can lead to misleading conclusions. The main issue with MACE in this particular review was using target vessel revascularisation or target lesion revascularisation as a component of MACE. This was problematic for several reasons. Firstly, it is important to note that the decision of whether or not target vessel revascularisation will be performed is based on subjective opinion. As both treatment providers and participants in the included trials were not blinded to treatment allocation, target vessel revascularisation and target lesion revascularisation may introduce bias. Secondly, using a composite outcome consisting of safety outcomes (death and myocardial infarction) and outcomes presumed to be a measure of procedural effectiveness (target vessel revascularisation and target lesion revascularisation) could lead to erroneous conclusions (<a href="./references#CD012481-bbs2-0128" title="KipKE , HollabaughK , MarroquinOC , WilliamsDO . The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology2008;51(7):701-7. [PMID: 18279733]">Kip 2008</a>). We therefore decided not to use MACE as a composite outcome, and instead used a composite cardiovascular outcome consisting of cardiovascular mortality and myocardial infarction ('major cardiovascular events'). </p> <p>It must be noted that we found no evidence of a difference when assessing all‐cause mortality, cardiovascular mortality, and myocardial infarction, but the Trial Sequential Analysis showed that we did not have enough information to confirm or reject our anticipated intervention effects, so the lack of a shown difference on these clinical outcomes might be caused by lack of statistical power. </p> <p>Another limitation when assessing serious adverse events is that the results on serious adverse events were not comprehensively reported in any of the included trials (<a href="./references#CD012481-bbs2-0122" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737-9.">Ioannidis 2009</a>). The only serious adverse events reported were usually all‐cause mortality, cardiovascular mortality, myocardial infarction, and target vessel revascularisation. </p> </section> <section id="CD012481-sec-0171"> <h5 class="title">Patient group</h5> <p>Our primary analyses assessed the effects of drug‐eluting stents versus bare‐metal stents for acute coronary syndrome. During our literature search we found 14 trials pooling participants with both ACS and stable angina (<a href="./references#CD012481-bbs2-0053" title="KaiserC , Brunner-La RoccaH , BuserP , BonettiP , OsswaldS , LinkaA , et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet2005;366:921-9. ">BASKET 2005a</a>; <a href="./references#CD012481-bbs2-0054" title="">BASKET 2005b</a>; <a href="./references#CD012481-bbs2-0055" title="KaiserC , GalatiusS , ErneP , EberliF , AlberH , RickliH , et al. Drug-eluting versus bare-metal stents in large coronary arteries. New England Journal of Medicine2010;363(24):2310-9. [DOI: 10.1056/NEJMoa1009406] [PMID: 21080780]">BASKET‐PROVE I 2010</a>; <a href="./references#CD012481-bbs2-0056" title="KaiserC , GalatiusS , JegerR , GilgenN , Skov JensenJ , NaberCK , et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation2015;131(1):74-81. [DOI: 10.1161/CIRCULATIONAHA.114.013520] [PMID: 25411159]">BASKET‐PROVE II 2015</a>; <a href="./references#CD012481-bbs2-0057" title="IschingerT . European study of Axxion and Glycocalix long-term evaluation. Herz2006;31:596. ">EAGLE 2006</a>; <a href="./references#CD012481-bbs2-0058" title="ErglisA , NarbuteI , KumsarsI , JegereS , MintaleI , ZakkeI , et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. Journal of the American College of Cardiology2007;50(6):491-7. ">Erglis 2007</a>; <a href="./references#CD012481-bbs2-0059" title="CostaRA , LanskyAJ , MintzGS , MehranR , TsuchiyaY , NegoitaM , et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). American Journal of Cardiology2005;95(1):113–6. GrubeE , SonodaS , IkenoF , HondaY , KarS , ChanC , et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation2004;109:2168–71. ">FUTURE I 2004</a>; <a href="./references#CD012481-bbs2-0060" title="StorgerH , GrubeE , HofmannM , SchwartzF , HaaseJ . Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. Journal of Interventional Cardiology2004;17(6):387-90. ">FUTURE II 2004</a>; <a href="./references#CD012481-bbs2-0061" title="HanYL , WangSL , JingQM , YuHB , WangB , MaYY , et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chinese Medical Journal2007;120(7):552–6. ">Han 2007</a>; <a href="./references#CD012481-bbs2-0062" title="LiS , FuX , LiuJ , WuW , GuX , MaN , et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary small vessel lesions. American Journal of Cardiology2004;94(6A):218E. ">Li 2004</a>; <a href="./references#CD012481-bbs2-0063" title="BønaaKH , MannsverkJ , WisethR , AabergeL , MyrengY , NygårdO , et al. Drug-eluting or bare-metal stents for coronary artery disease. New England Journal of Medicine2016;375:1242-52. ">NORSTENT 2016</a>; <a href="./references#CD012481-bbs2-0064" title="ValgimigliM , CampoG , PercocoG , MontiM , FerrariF , TumscitzC , et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal2010;160(5):804-11. [PMID: 21095265]ValgimigliM , TebaldiM , BorghesiM , BranckxP , CampoG , TumscitzC , et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention. JACC: Cardiovascular Interventions2014;7(1):20-8. [PMID: 24332420]">PRODIGY 2014</a>; <a href="./references#CD012481-bbs2-0065" title="ArdissinoD , CavalliniC , BramucciE , IndolfiC , MarzocchiA , ManariA , et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA2004;292(22):2727-34. [PMID: 15585732]">SES‐SMART 2004</a>; <a href="./references#CD012481-bbs2-0066" title="deBelderA , dela Torre HernandezJM , Lopez-PalopR , O'KaneP , HernandezFH , StrangeJ , et al. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians. Journal of the American College of Cardiology2014;63(14):1371-5. [DOI: 10.1016/j.jacc.2013.10.053] [PMID: 24216285]">XIMA 2014</a>; <a href="./references#CD012481-bbs2-0067" title="ValgimigliM , PatialiakasA , ThuryA , ColangeloS , CampoG , TebaldiM , et al. Randomized comparison of zotarolimus-eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates study. American Heart Journal2013;166(5):831-8. [PMID: 24176438]ValgimigliM , PatialiakasA , ThuryA , McFaddenE , ColangeloS , CampoG , et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. Journal of the American College of Cardiology2015;65(8):805-15. [PMID: 25720624]">ZEUS 2015</a>). The results were similar to our primary results except for the outcome major cardiovascular events (RR 0.72, 95% CI 0.60 to 0.85, I<sup>2</sup> = 26%, 17,628 participants, 12 trials) and myocardial infarction (RR 0.57, 95% CI 0.41 to 0.79, I<sup>2</sup> = 58%, 17,628 participants, 12 trials). </p> </section> </section> </section> <section id="CD012481-sec-0172"> <h3 class="title" id="CD012481-sec-0172">Agreements and disagreements with other studies or reviews</h3> <p>A 2010 Cochrane review compared drug‐eluting stents versus bare‐metal stents in participants with both ACS and stable ischaemic heart disease (<a href="./references#CD012481-bbs2-0101" title="GreenhalghJ , HockenhullJ , RaoN , DundarY , DicksonRC , BagustA . Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD004587. [DOI: 10.1002/14651858.CD004587.pub3]">Greenhalgh 2010</a>). They found no significant difference on all‐cause mortality, incidence of acute myocardial infarction, or thrombosis. However, the review showed indications of beneficial effects of drug‐eluting stents compared with bare‐metal stents on target lesion revascularisation, target vessel revascularisation, and a composite outcome of cardiac events. They did not perform Trial Sequential Analysis or another method to assess the risk of random error, neither did they assess the strength of evidence for the alternative hypothesis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> <p>We identified three previous reviews assessing the effects of drug‐eluting stents versus bare‐metal stents in STEMI participants. All three reviews confirmed our results showing that there is no difference between drug‐eluting stents and bare‐metal stents on all‐cause mortality. </p> <p><a href="./references#CD012481-bbs2-0088" title="De LucaG , DirksenMT , SpauldingC , KelbaekH , SchalijM , ThuesenL , et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Archives of Internal Medicine2012;172(8):611-21.">De Luca 2012</a> found no difference in terms of mortality at 440 days of follow‐up (hazard ratio (HR) 0.85, 95% CI 0.70 to 1.04, P = 0.11). No difference in stent thrombosis was also observed. A significant reduction in target vessel revascularisation was found (HR 0.57, 95% CI 0.50 to 0.66, P = 0.001). They did not perform Trial Sequential Analysis or other method to assess the risk of random error, neither did they assess the strength of evidence for the alternative hypothesis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> <p><a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a> included 14 trials and found no evidence of an effect on mortality (RR 0.88, 95% CI 0.70 to 1.10, P = 0.26). <a href="./references#CD012481-bbs2-0181" title="SuhHS , SongHJ , ChoiJE , JangEJ , SonHJ , LeeSM , et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis. International Journal of Technology Assessment in Health Care2011;27(1):11-22. [PMID: 21262083]">Suh 2011</a> found evidence of an effect on myocardial infarction (RR 0.77, 95% CI 0.77 to 0.97, P = 0.03), but did not perform Trial Sequential Analysis or other method to assess the risk of random error, nor did they assess the strength of evidence for the alternative hypothesis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> <p><a href="./references#CD012481-bbs2-0200" title="ZhengF , XingS , GongZ , XingQ . Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart, Lung &amp; Circulation2014;23(6):542-8. [PMID: 24529648]">Zheng 2014</a> found no difference in terms of mortality in a meta‐analysis of four trials all with a minimum follow‐up of four years (odds ratio (OR) 0.85, 95% CI 0.59 to 1.20, P = 0.35) or stent thrombosis (OR 3.03, 95% CI 1.28 to 7.18, P = 0.01). Additionally, <a href="./references#CD012481-bbs2-0200" title="ZhengF , XingS , GongZ , XingQ . Five-year outcomes for first generation drug-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised controlled trials. Heart, Lung &amp; Circulation2014;23(6):542-8. [PMID: 24529648]">Zheng 2014</a> also found a reduction in target vessel revascularisation (OR 0.55, 95% CI 0.55 to 0.77). They did not perform Trial Sequential Analysis or other method to assess the risk of random error, neither did they assess the strength of evidence for the alternative hypothesis (<a href="./references#CD012481-bbs2-0124" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012481-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-01" target="_blank"><b></b></a></p> </div><img alt="study flow diagram." data-id="CD012481-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012481-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012481-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on all‐cause mortality at maximum follow‐up in 21 trials. The diversity‐adjusted required information size (RIS) was calculated based on mortality in the control group of 7.76%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 45,046 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines). The cumulative Z‐curve did not cross the inner‐wedge futility line (the inner‐wedge futility could not be calculated due to too little information). Additionally, the cumulative Z‐score did not cross the RIS. The green dotted line shows conventional boundaries (2.0%)." data-id="CD012481-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on all‐cause mortality at maximum follow‐up in 21 trials. The diversity‐adjusted required information size (RIS) was calculated based on mortality in the control group of 7.76%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 45,046 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines). The cumulative Z‐curve did not cross the inner‐wedge futility line (the inner‐wedge futility could not be calculated due to too little information). Additionally, the cumulative Z‐score did not cross the RIS. The green dotted line shows conventional boundaries (2.0%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on serious adverse events at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of serious adverse events in the control group of 22.95%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 24,853 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (2.0%)." data-id="CD012481-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on serious adverse events at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of serious adverse events in the control group of 22.95%; risk ratio reduction (RRR) of 10% in the experimental group; type I error of 2.0%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 24,853 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (2.0%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on target vessel revascularisation at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of target vessel revascularisations in the control group of 13.28%; risk ratio reduction (RRR) of 30% in the experimental group; type I error of 3.33%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 5361 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (3.33%)." data-id="CD012481-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Trial Sequential Analysis of drug‐eluting stents versus bare‐metal stents on target vessel revascularisation at maximum follow‐up in 22 trials. The diversity‐adjusted required information size (RIS) was calculated based on a rate of target vessel revascularisations in the control group of 13.28%; risk ratio reduction (RRR) of 30% in the experimental group; type I error of 3.33%; and type II error of 20% (80% power). No diversity was noted. The diversity‐adjusted required information size was 5361 participants. The cumulative Z‐curve (blue line) crossed the trial sequential monitoring boundaries for benefit. The green dotted line shows conventional boundaries (3.33%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 1: All‐cause mortality" data-id="CD012481-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 2: All‐cause mortality best‐worst" data-id="CD012481-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 2: All‐cause mortality best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 3: All‐cause mortality worst‐best" data-id="CD012481-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 3: All‐cause mortality worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 4: All‐cause mortality according to type of drug‐eluting stent" data-id="CD012481-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 4: All‐cause mortality according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 5: All‐cause mortality according to type of ACS" data-id="CD012481-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 5: All‐cause mortality according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 6: All‐cause mortality according to length of maximum follow‐up" data-id="CD012481-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 6: All‐cause mortality according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 7: All‐cause mortality according to registration status" data-id="CD012481-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 7: All‐cause mortality according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 8: Serious adverse events" data-id="CD012481-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 8: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 9: Serious adverse events best‐worst" data-id="CD012481-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 9: Serious adverse events best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 10: Serious adverse events worst‐best" data-id="CD012481-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 10: Serious adverse events worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 11: Serious adverse events according to type of drug‐eluting stent" data-id="CD012481-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 11: Serious adverse events according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 12: Serious adverse events according to type of ACS" data-id="CD012481-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 12: Serious adverse events according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 13: Serious adverse events according to length of maximum follow‐up" data-id="CD012481-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 13: Serious adverse events according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 14: Serious adverse events according to registration status" data-id="CD012481-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 14: Serious adverse events according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 15: Major cardiovascular events" data-id="CD012481-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 15: Major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 16: Major cardiovascular events best‐worst" data-id="CD012481-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 16: Major cardiovascular events best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 17: Major cardiovascular events worst‐best" data-id="CD012481-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 17: Major cardiovascular events worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 18: Major cardiovascular events according to type of drug‐eluting stent" data-id="CD012481-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 18: Major cardiovascular events according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 19: Major cardiovascular events according to type of ACS" data-id="CD012481-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 19: Major cardiovascular events according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 20: Major cardiovascular events according to length of maximum follow‐up" data-id="CD012481-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 20: Major cardiovascular events according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 21: Major cardiovascular events according to registration status" data-id="CD012481-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 21: Major cardiovascular events according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 22: Cardiovascular mortality" data-id="CD012481-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 22: Cardiovascular mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 23: Cardiovascular mortality best‐worst" data-id="CD012481-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 23: Cardiovascular mortality best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 24: Cardiovascular mortality worst‐best" data-id="CD012481-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 24: Cardiovascular mortality worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 25: Cardiovascular mortality according to type of drug‐eluting stent" data-id="CD012481-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 25: Cardiovascular mortality according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 26: Cardiovascular mortality according to type of ACS" data-id="CD012481-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 26: Cardiovascular mortality according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 27: Cardiovascular mortality according to length of maximum follow‐up" data-id="CD012481-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 27: Cardiovascular mortality according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 28: Cardiovascular mortality according to registration status" data-id="CD012481-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 28: Cardiovascular mortality according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 29: Myocardial infarction" data-id="CD012481-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 29: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 30: Myocardial infarction best‐worst" data-id="CD012481-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 30: Myocardial infarction best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 31: Myocardial infarction worst‐best" data-id="CD012481-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 31: Myocardial infarction worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 32: Myocardial infarction according to type of drug‐eluting stent" data-id="CD012481-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 32: Myocardial infarction according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 33: Myocardial infarction according to type of ACS" data-id="CD012481-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 33: Myocardial infarction according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 34: Myocardial infarction according to length of maximum follow‐up" data-id="CD012481-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 34: Myocardial infarction according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 35: Myocardial infarction according to registration status" data-id="CD012481-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 35: Myocardial infarction according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 36: Stent thrombosis" data-id="CD012481-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 36: Stent thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 37: Stent thrombosis best‐worst" data-id="CD012481-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 37: Stent thrombosis best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 38: Stent thrombosis worst‐best" data-id="CD012481-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 38: Stent thrombosis worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 39: Stent thrombosis according to type of drug‐eluting stent" data-id="CD012481-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 39: Stent thrombosis according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 40: Stent thrombosis according to type of ACS" data-id="CD012481-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 40: Stent thrombosis according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 41: Stent thrombosis according to length of maximum follow‐up" data-id="CD012481-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 41: Stent thrombosis according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 42: Stent thrombosis according to registration status" data-id="CD012481-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 42: Stent thrombosis according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.42.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.43" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 43: Target vessel revascularisation" data-id="CD012481-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.43.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.43.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 43: Target vessel revascularisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.43.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.44" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 44: Target vessel revascularisation best‐worst" data-id="CD012481-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.44.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.44.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 44: Target vessel revascularisation best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.44.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.45" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 45: Target vessel revascularisation worst‐best" data-id="CD012481-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.45.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.45.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 45: Target vessel revascularisation worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.45.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.46" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 46: Target vessel revascularisation according to type of drug‐eluting stent" data-id="CD012481-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.46.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.46.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 46: Target vessel revascularisation according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.46.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.47" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 47: Target vessel revascularisation according to type of ACS" data-id="CD012481-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.47.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.47.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 47: Target vessel revascularisation according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.47.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.48" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 48: Target vessel revascularisation according to length of maximum follow‐up" data-id="CD012481-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.48.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.48.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 48: Target vessel revascularisation according to length of maximum follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.48.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-001.49" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 49: Target vessel revascularisation according to registration status" data-id="CD012481-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.49.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-001.49.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up, Outcome 49: Target vessel revascularisation according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-001.49.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 1: All‐cause mortality" data-id="CD012481-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 2: All‐cause mortality best‐worst" data-id="CD012481-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 2: All‐cause mortality best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 3: All‐cause mortality worst‐best" data-id="CD012481-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 3: All‐cause mortality worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 4: All‐cause mortality according to type of drug‐eluting stent" data-id="CD012481-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 4: All‐cause mortality according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 5: All‐cause mortality according to type of ACS" data-id="CD012481-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 5: All‐cause mortality according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 6: All‐cause mortality according to registration status" data-id="CD012481-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 6: All‐cause mortality according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 7: Serious adverse events" data-id="CD012481-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 7: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 8: Serious adverse events best‐worst" data-id="CD012481-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 8: Serious adverse events best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 9: Serious adverse events worst‐best" data-id="CD012481-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 9: Serious adverse events worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 10: Serious adverse events according to type of drug‐eluting stent" data-id="CD012481-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 10: Serious adverse events according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 11: Serious adverse events according to type of ACS" data-id="CD012481-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 11: Serious adverse events according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 12: Serious adverse events according to registration status" data-id="CD012481-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 12: Serious adverse events according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 13: Major cardiovascular events" data-id="CD012481-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 13: Major cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 14: Major cardiovascular events best‐worst" data-id="CD012481-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 14: Major cardiovascular events best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 15: Major cardiovascular events worst‐best" data-id="CD012481-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 15: Major cardiovascular events worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 16: Major cardiovascular events according to type of drug‐eluting stent" data-id="CD012481-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 16: Major cardiovascular events according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 17: Major cardiovascular events according to type of ACS" data-id="CD012481-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 17: Major cardiovascular events according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 18: Major cardiovascular events according to registration status" data-id="CD012481-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 18: Major cardiovascular events according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 19: Cardiovascular mortality" data-id="CD012481-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 19: Cardiovascular mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 20: Cardiovascular mortality best‐worst" data-id="CD012481-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 20: Cardiovascular mortality best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 21: Cardiovascular mortality worst‐best" data-id="CD012481-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 21: Cardiovascular mortality worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 22: Cardiovascular mortality according to type of drug‐eluting stent" data-id="CD012481-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 22: Cardiovascular mortality according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 23: Cardiovascular mortality according to type of ACS" data-id="CD012481-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 23: Cardiovascular mortality according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 24: Cardiovascular mortality according to registration status" data-id="CD012481-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 24: Cardiovascular mortality according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 25: Myocardial infarction" data-id="CD012481-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 25: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 26: Myocardial infarction best‐worst" data-id="CD012481-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 26: Myocardial infarction best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 27: Myocardial infarction worst‐best" data-id="CD012481-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 27: Myocardial infarction worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 28: Myocardial infarction according to type of drug‐eluting stent" data-id="CD012481-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 28: Myocardial infarction according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 29: Myocardial infarction according to type of ACS" data-id="CD012481-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 29: Myocardial infarction according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 30: Myocardial infarction according to registration status" data-id="CD012481-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 30: Myocardial infarction according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 31: Stent thrombosis" data-id="CD012481-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 31: Stent thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 32: Stent thrombosis best‐worst" data-id="CD012481-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 32: Stent thrombosis best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 33: Stent thrombosis worst‐best" data-id="CD012481-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 33: Stent thrombosis worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 34: Stent thrombosis according to type of drug‐eluting stent" data-id="CD012481-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 34: Stent thrombosis according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 35: Stent thrombosis according to type of ACS" data-id="CD012481-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 35: Stent thrombosis according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 36: Stent thrombosis according to registration status" data-id="CD012481-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 36: Stent thrombosis according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 37: Target vessel revascularisation" data-id="CD012481-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 37: Target vessel revascularisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 38: Target vessel revascularisation best‐worst" data-id="CD012481-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 38: Target vessel revascularisation best‐worst </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 39: Target vessel revascularisation worst‐best" data-id="CD012481-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 39: Target vessel revascularisation worst‐best </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.40" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 40: Target vessel revascularisation according to type of drug‐eluting stent" data-id="CD012481-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.40.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.40.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 40: Target vessel revascularisation according to type of drug‐eluting stent </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.40.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.41" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 41: Target vessel revascularisation according to type of ACS" data-id="CD012481-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.41.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.41.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 41: Target vessel revascularisation according to type of ACS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.41.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012481-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/urn:x-wiley:14651858:media:CD012481:CD012481-CMP-002.42" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 42: Target vessel revascularisation according to registration status" data-id="CD012481-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.42.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_t/tCD012481-CMP-002.42.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2: Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month, Outcome 42: Target vessel revascularisation according to registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/media/CDSR/CD012481/image_n/nCD012481-CMP-002.42.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012481-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with acute coronary syndrome<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Drug‐eluting stents<br/><b>Comparison:</b> Bare‐metal stents </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bare‐metal stents</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with drug‐eluting stents</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.78 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,250<br/>(21 RCTs/22 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (21 trials reporting on 22 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000<br/>(60 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.74 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11,724<br/>(22 RCTs/23 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that the boundary for benefit was breached, hence the risk of imprecision of the outcome result is low. Multiple eligible treatments were used in 1 trial, generating a further comparison (22 trials reporting on 23 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000<br/>(170 to 197) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major cardiovascular events at maximum<br/>follow‐up </p> <p>Follow‐up: median 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.83 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,939<br/>(19 RCTs/20 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (19 trials reporting on 20 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(55 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life at maximum follow‐up ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.76 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9248<br/>(14 RCTs/15 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (14 trials reporting on 15 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(44 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction at maximum follow‐up<br/>Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/>(0.82 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,217<br/>(18 RCTs/19 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Trial Sequential Analysis for a RRR of 10% showed that neither the boundary for futility, benefit or harm was breached, hence the risk of imprecision of the outcome result is high. Multiple eligible treatments were used in 1 trial, generating a further comparison (18 trials reporting on 19 experimental groups). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(39 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angina at maximum follow‐up ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>RRR:</b> risk ratio reduction </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for serious risk of imprecision due to our required information size not being met.<br/><sup>2</sup>Downgraded one level for serious risk of bias due to all trials being at high risk of bias, but as mortality is a more objective outcome, lack of blinding of participants, personnel and outcome assessors may not bias the outcome as much.<br/><sup>3</sup>Downgraded two levels for very serious risk of bias due to all trials being at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Drug‐eluting stents compared to bare‐metal stents for acute coronary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/full#CD012481-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012481-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.99, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.54, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.54, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.91, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.02, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause mortality according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.29, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.54, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.55, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.54, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious adverse events best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.62, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serious adverse events worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Serious adverse events according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.58, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.76, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.17, 10.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.54, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.7 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.52, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Serious adverse events according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.75, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.29, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 NSTEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.50, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Serious adverse events according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.47, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.75, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Serious adverse events according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.55, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.75, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Major cardiovascular events best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.39, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Major cardiovascular events worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.97, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Major cardiovascular events according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.58, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.81, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.60, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.7 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.54, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Major cardiovascular events according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Major cardiovascular events according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.48, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Major cardiovascular events according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.47, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Cardiovascular mortality best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.32, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Cardiovascular mortality worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.06, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Cardiovascular mortality according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.58, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.52, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.17, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Cardiovascular mortality according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Cardiovascular mortality according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.65, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.23, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Cardiovascular mortality according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.16, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Myocardial infarction best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.33, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Myocardial infarction worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.00, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Myocardial infarction according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.36, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.79, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.75, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.40, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.7 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.54, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Myocardial infarction according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Myocardial infarction according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.52, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.58, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.24, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.80, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Myocardial infarction according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.36, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.85, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.44, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Stent thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.37 Stent thrombosis best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.32, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.38 Stent thrombosis worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.12, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.39 Stent thrombosis according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.3 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.73, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.4 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.76, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.5 Zotarolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.6 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.52, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.39.7 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.82, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.40 Stent thrombosis according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.40.2 NSTEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.12, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.41 Stent thrombosis according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.82, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.25, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.41.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.42 Stent thrombosis according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.42.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.22, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.43 Target vessel revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.44 Target vessel revascularisation best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.37, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.45 Target vessel revascularisation worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.46 Target vessel revascularisation according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.1 Biodegradable (Biolimus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.29, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.2 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.42, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.44, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.4 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.53, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.5 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.35, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.6 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.82, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.46.7 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.32, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.47 Target vessel revascularisation according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.53, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.2 Acute coronary syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.47.3 NSTEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.18, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.48 Target vessel revascularisation according to length of maximum follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.1 Less or equal to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.25, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.2 Between 6 and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.43, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.3 Between 1 and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.19, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.4 More or equal to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.54, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.48.5 Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.49 Target vessel revascularisation according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.52, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.28, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.53, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.49.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1083</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.38, 0.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012481-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 All‐cause mortality worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause mortality according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.42, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.26, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All‐cause mortality according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 All‐cause mortality according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.41, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.47, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Serious adverse events best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.40, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Serious adverse events worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.52, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Serious adverse events according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.30, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Serious adverse events according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Serious adverse events according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.45, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.43, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Major cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Major cardiovascular events best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Major cardiovascular events worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.53, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Major cardiovascular events according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.32, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.25, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Major cardiovascular events according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Major cardiovascular events according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.41, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.24, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Cardiovascular mortality best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.32, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Cardiovascular mortality worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.54, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Cardiovascular mortality according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.30, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.13, 6.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Cardiovascular mortality according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Cardiovascular mortality according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.43, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.39, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.27, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.26 Myocardial infarction best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.20, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.27 Myocardial infarction worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.41, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.28 Myocardial infarction according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.19, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.09, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.20, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.29 Myocardial infarction according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.30 Myocardial infarction according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.07, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.31 Stent thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.32 Stent thrombosis best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.20, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.33 Stent thrombosis worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.34 Stent thrombosis according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.34.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.15, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.34.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.34.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.23, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.35 Stent thrombosis according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.35.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.36 Stent thrombosis according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.36.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.36.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.25, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.36.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.06, 14.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.37 Target vessel revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.38 Target vessel revascularisation best‐worst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.39 Target vessel revascularisation worst‐best <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.40 Target vessel revascularisation according to type of drug‐eluting stent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.1 Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40.3 Sirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.29, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.41 Target vessel revascularisation according to type of ACS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.41.1 STEMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.42 Target vessel revascularisation according to registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.1 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.2 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.32, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42.3 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.09, 1.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome at one month</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012481.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012481-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012481-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012481-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012481-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012481\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012481\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012481\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012481\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012481\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012481.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012481.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012481.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012481.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012481.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726221115"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012481.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726221119"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012481.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8e57bad4f431',t:'MTc0MDcyNjIyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 